US20020037914A1 - Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins - Google Patents

Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins Download PDF

Info

Publication number
US20020037914A1
US20020037914A1 US09774555 US77455501A US2002037914A1 US 20020037914 A1 US20020037914 A1 US 20020037914A1 US 09774555 US09774555 US 09774555 US 77455501 A US77455501 A US 77455501A US 2002037914 A1 US2002037914 A1 US 2002037914A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
group
groups
substituted
selected
group consisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09774555
Inventor
Mitchell DeLong
John McIver
Robert Youngquist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing sulfur

Abstract

A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.

Description

    FIELD OF THE INVENTION
  • This invention relates to compositions and methods for treating hair loss in mammals. More particularly, this invention relates to compositions and methods for arresting or reversing hair loss, or both, and promoting hair growth. [0001]
  • BACKGROUND OF THE INVENTION
  • Hair loss is a common problem which is, for example, naturally occurring or chemically promoted through the use of certain therapeutic drugs designed to alleviate conditions such as cancer. Often such hair loss is accompanied by lack of hair re-growth which causes partial or full baldness. [0002]
  • Hair growth on the scalp does not occur continuously, but rather occurs by a cycle of activity involving alternating periods of growth and rest. This cycle is divided into three main stages; anagen, catagen, and telogen. Anagen is the growth phase of the cycle and is characterized by penetration of the hair follicle deep into the dermis with rapid proliferation of cells which are differentiating to form hair. The next phase is catagen, which is a transitional stage marked by the cessation of cell division, and during which the hair follicle regresses through the dermis and hair growth ceases. The next phase, telogen, is characterized as the resting stage during which the regressed follicle contains a germ with tightly packed dermal papilla cells. At telogen, the initiation of a new anagen phase is caused by rapid cell proliferation in the germ, expansion of the dermal papilla, and elaboration of basement membrane components. When hair growth ceases, most of the hair follicles reside in telogen and anagen is not engaged, thus causing the onset of full or partial baldness. [0003]
  • Attempts to invoke the re-growth of hair have been made by, for example, the promotion or prolongation of anagen. Currently, there are two drugs approved by the United States Food and Drug Administration for the treatment of male pattern baldness: topical minoxidil (marketed as ROGAINE® by Pharmacia & Upjohn), and oral finasteride (marketed as PROPECIA® by Merck & Co., Inc.). However, the search for efficacious hair growth inducers is ongoing due to factors including safety concerns and limited efficacy. [0004]
  • The thyroid hormone thyroxine (“T4”) converts to thyronine (“T3”) in human skin by deiodinase I, a selenoprotein. Selenium deficiency causes a decrease in T3 levels due to a decrease in deiodinase I activity; this reduction in T3 levels is strongly associated with hair loss. Consistent with this observation, hair growth is a reported side effect of administration of T4. See, e.g., Berman, “Peripheral Effects of L-Thyroxine on Hair Growth and Coloration in Cattle”, [0005] Journal of Endocrinology, Vol. 20, pp. 282-292 (1960); and Gunaratnam, “The Effects of Thyroxine on Hair Growth in the Dog”, J. Small Anim. Pract., Vol. 27, pp. 17-29 (1986). Furthermore, T3 and T4 have been the subject of several patent publications relating to treatment of hair loss. See, e.g., Fischer et al., DE 1,617,477, published Jan. 8, 1970; Mortimer, GB 2,138,286, published Oct. 24, 1984; and Lindenbaum, WO 96/25943, assigned to Life Medical Sciences, Inc., published Aug. 29, 1996.
  • Unfortunately, however, administration of T3 or T4, or both, to treat hair loss is often not practicable because these thyroid hormones can induce significant cardiotoxicity. See, e.g., Walker et al., U.S. Pat. No. 5,284,971, assigned to Syntex, issued Feb. 8, 1994 and Emmett et al., U.S. Pat. No. 5,061,798, assigned to Smith Kline & French Laboratories, issued Oct. 29, 1991. [0006]
  • In an alternative approach, prostaglandins have been proposed to promote hair growth because prostaglandins may have a similar benefit to thyroid hormones, i.e., increasing hair length and changing pigmentation. Naturally occurring prostaglandins (e.g., PGA[0007] 2, PGB2, PGE1, PGF, and PGI2) are C-20 unsaturated fatty acids. PGF, the naturally occurring Prostaglandin F analog in humans, is characterized by hydroxyl groups at the C9 and C11 positions on the alicyclic ring, a cis-double bond between C5 and C6, and a trans-double bond between C 13 and C 14. PGFhas the formula:
    Figure US20020037914A1-20020328-C00001
  • Analogs of naturally occurring Prostaglandin F are known in the art. For example, see U.S. Pat. No. 4,024,179 issued to Bindra and Johnson on May 17, 1977; German Patent No. DT-002,460,990 issued to Beck, Lerch, Seeger, and Teufel published on Jul. 1, 1976; U.S. Pat. No. 4,128,720 issued to Hayashi, Kori, and Miyake on Dec. 5, 1978; U.S. Pat. No. 4,011,262 issued to Hess, Johnson, Bindra, and Schaaf on Mar. 8, 1977; U.S. Pat. No. 3,776,938 issued to Bergstrom and Sjovall on Dec. 4, 1973; P. W. Collins and S. W. Djuric, “Synthesis of Therapeutically Useful Prostaglandin and Prostacyclin Analogs”, [0008] Chem. Rev., Vol. 93, pp. 1533-1564 (1993); G. L. Bundy and F. H. Lincoln, “Synthesis of 17-Phenyl-18,19,20-Trinorprostaglandins: I. The PG1 Series”, Prostaglandin, Vol. 9 No. 1, pp. 1-4 (1975); W. Bartman, G. Beck, U. Lerch, H. Teufel, and B. Scholkens, “Luteolytic Prostaglandin: Synthesis and Biological Activity”, Prostaglandin, Vol. 17 No. 2, pp. 301-311 (1979); C. Iiljebris, G. Selen, B. Resul, J. Sternschantz, and U. Hacksell, “Derivatives of 17-Phenyl-18, 19,20-trinorprostaglandin F2α. Isopropyl Ester: Potential Antiglaucoma Agents”, Journal of Medicinal Chemistry, Vol. 38, No. 2, pp. 289-304, (1995).
  • Prostaglandins in general have a wide range of biological activities. For example, PGE[0009] 2 has the following properties: a) regulator of cell proliferation, b) regulator of cytokine synthesis, c) regulator of immune responses and d) inducer of vasodilatation. Vasodilatation is thought to be one of the mechanisms of how minoxidil provides a hair growth benefit. In vitro results in the literature also indicate some anti-inflammatory properties of the prostaglandins. c.f.; Tanaka, H., Br J. Pharm., 116, 2298, (1995).
  • However, previous attempts at using prostaglandins to promote hair growth have been unsuccessful. Different prostaglandin analogs can bind to multiple receptors at various concentrations with a biphasic effect. Furthermore, administration of naturally occurring prostaglandins can cause side effects such as inflammation, surface irritation, smooth muscle contraction, pain, and bronchoconstriction. Therefore, it is an object of this invention to provide methods for using prostaglandin analogs to grow hair and to provide compositions that promote hair growth in humans and lower animals. It is a further object of this invention to provide a selection of appropriate prostaglandin analogs that will promote hair growth and that do not cause significant undesirable side effects. [0010]
  • SUMMARY OF THE INVENTION
  • This invention relates to compositions and methods for treating hair loss. The methods comprise administering the compositions comprising specific prostaglandin F analogs that interact strongly with hair-selective receptors, such as the FP receptor. The choice of prostaglandin F analog is important because it must selectively activate the FP receptor and not activate any other receptors that would negate the effect of activating the FP receptor. The compositions comprise: component A) the prostaglandin F analog, component B) a carrier, and optionally component C) an activity enhancer. [0011]
  • Suitable prostaglandin F analogs (“PGF's”) for this invention have the general formula: [0012]
    Figure US20020037914A1-20020328-C00002
  • wherein R[0013] 1 is preferably CO2H or CO2CH3; R2 is preferably H; R3 and R4 are preferably H or CH3; X is preferably OH; Y is selected from the group consisting of a divalent hydrocarbon group, O, S, S(O), S(O)2, and NR11, wherein R11 is preferably a hydrogen atom or a methyl group; and Z is preferably thienyl or phenyl. Other suitable PGF's are pharmaceutically acceptable salts, hydrates, and biohydrolyzable amides, esters, and imides of the general formula above. Optical isomers, diastereomers, and enantiomers of the structure described above are also suitable for this invention. At all stereocenters where stereochemistry is not defined (i.e., C11, C12, C15, and C16), both epimers are envisioned with the epimer that corresponds to the naturally-occurring one being preferred.
  • DETAILED DESCRIPTION OF THE INVENTION
  • This invention relates to compositions comprising prostaglandin F analogs (“PGF's”) to treat hair loss in mammals. “Treating hair loss” includes arresting hair loss or reversing hair loss, or both, and promoting hair growth. [0014]
  • Publications and patents are referred to throughout this disclosure. All U.S. patents cited herein are hereby incorporated by reference. [0015]
  • All percentages, ratios, and proportions used herein are by weight unless otherwise specified. [0016]
  • Definition and Usage of Terms
  • The following is a list of definitions for terms, as used herein: [0017]
  • “Activate” means binding and signal transduction of a receptor. [0018]
  • “Acyl group” means a monovalent group suitable for acylating a nitrogen atom to form an amide or carbamate, an alcohol to form a carbonate, or an oxygen atom to form an ester group. Preferred acyl groups include benzoyl, acetyl, tert-butyl acetyl, para-phenyl benzoyl, and trifluoroacetyl. More preferred acyl groups include acetyl and benzoyl. The most preferred acyl group is acetyl. [0019]
  • “Aromatic group” means a monovalent group having a monocyclic ring structure or fused bicyclic ring structure. Monocyclic aromatic groups contain 5 to 10 carbon atoms, preferably 5 to 7 carbon atoms, and more preferably 5 to 6 carbon atoms in the ring. Bicyclic aromatic groups contain 8 to 12 carbon atoms, preferably 9 or 10 carbon atoms in the ring. Aromatic groups are unsubstituted. The most preferred aromatic group is phenyl. [0020]
  • “Carbocyclic group” means a monovalent saturated or unsaturated hydrocarbon ring. Carbocyclic groups are monocyclic, or are fused, spiro, or bridged bicyclic ring systems. Monocyclic carbocyclic groups contain 4 to 10 carbon atoms, preferably 4 to 7 carbon atoms, and more preferably 5 to 6 carbon atoms in the ring. Bicyclic carbocyclic groups contain 8 to 12 carbon atoms, preferably 9 to 10 carbon atoms in the ring. Carbocyclic groups are unsubstituted. Preferred carbocyclic groups include cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. More preferred carbocyclic groups include cyclohexyl, cycloheptyl, and cyclooctyl. The most preferred carbocyclic group is cycloheptyl. Carbocyclic groups are not aromatic. [0021]
  • “Cyano group” means a group containing a nitrile functionality. [0022]
  • “FP agonist” means a compound that activates the FP receptor. [0023]
  • “FP receptor” means known human FP receptors, their splice variants, and undescribed receptors that have similar binding and activation profiles as the known human FP receptors. “FP” means the receptor is of the class which has the highest affinity for PGF[0024] of all the naturally occurring prostaglandins. FP refers to a known protein.
  • “Halogen atom” means F, Cl, Br, or I. Preferably, the halogen atom is F, Cl, or Br; more preferably Cl or F; and most preferably F. [0025]
  • “Halogenated heterogenous group” means a substituted heterogenous group or a substituted heterocyclic group, wherein at least one substituent is a halogen atom. Halogenated heterogenous groups can have a straight, branched, or cyclic structure. Preferred halogenated heterogenous groups have 1 to 12 carbon atoms, more preferably 1 to 6 carbon atoms, and most preferably 1 to 3 carbon atoms. Preferred halogen atom substituents are Cl and F. [0026]
  • “Halogenated hydrocarbon group” means a substituted monovalent hydrocarbon group or a substituted carbocyclic group, wherein at least one substituent is a halogen atom. Halogenated hydrocarbon groups can have a straight, branched, or cyclic structure. Preferred halogenated hydrocarbon groups have 1 to 12 carbon atoms, more preferably 1 to 6 carbon atoms, and most preferably 1 to 3 carbon atoms. Preferred halogen atom substituents are Cl and F. The most preferred halogenated hydrocarbon group is trifluoromethyl. [0027]
  • “Heteroaromatic group” means an aromatic ring containing carbon and 1 to 4 heteroatoms in the ring. Heteroaromatic groups are monocyclic or fused bicyclic rings. Monocyclic heteroaromatic groups contain 5 to 10 member atoms (i.e., carbon and heteroatoms), preferably 5 to 7, and more preferably 5 to 6 in the ring. Bicyclic heteroaromatic rings contain 8 to 12 member atoms, preferably 9 or 10 in the ring. Heteroaromatic groups are unsubstituted. Preferred heteroaromatic groups include thienyl, thiazolyl, purinyl, pyrimidyl, pyridyl, and furanyl. More preferred heteroaromatic groups include thienyl, furanyl, and pyridyl. The most preferred heteroaromatic group is thienyl. [0028]
  • “Heteroatom” means an atom other than carbon in the ring of a heterocyclic group or the chain of a heterogeneous group. Preferably, heteroatoms are selected from the group consisting of nitrogen, sulfur, and oxygen atoms. Groups containing more than one heteroatom may contain different heteroatoms. [0029]
  • “Heterocyclic group” means a saturated or unsaturated ring structure containing carbon and 1 to 4 heteroatoms in the ring. No two heteroatoms are adjacent in the ring. Heterocyclic groups are not aromatic. Heterocyclic groups are monocyclic, or are fused or bridged bicyclic ring systems. Monocyclic heterocyclic groups contain 4 to 10 member atoms (i.e., including both carbon atoms and at least 1 heteroatom), preferably 4 to 7, and more preferably 5 to 6 in the ring. Bicyclic heterocyclic groups contain 8 to 12 member atoms, preferably 9 or 10 in the ring. Heterocyclic groups are unsubstituted. Preferred heterocyclic groups include piperzyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and piperdyl. [0030]
  • “Heterogeneous group” means a saturated or unsaturated chain containing 1 to 18 member atoms (i.e., including both carbon and at least one heteroatom). No two heteroatoms are adjacent. Preferably, the chain contains 1 to 12 member atoms, more preferably 1 to 6, and most preferably 1 to 4. The chain may be straight or branched. Preferred branched heterogeneous groups have one or two branches, preferably one branch. Preferred heterogeneous groups are saturated. Unsaturated heterogeneous groups have one or more double bonds, one or more triple bonds, or both. Preferred unsaturated heterogeneous groups have one or two double bonds or one triple bond. More preferably, the unsaturated heterogeneous group has one double bond. Heterogeneous groups are unsubstituted. [0031]
  • “Monovalent hydrocarbon group” means a chain of 1 to 18 carbon atoms, preferably 1 to 12 carbon atoms. “Lower monovalent hydrocarbon group” means a monovalent hydrocarbon group having 1 to 6, preferably 1 to 4 carbon atoms. Monovalent hydrocarbon groups may have a straight chain or branched chain structure. Preferred monovalent hydrocarbon groups have one or two branches, preferably 1 branch. Preferred monovalent hydrocarbon groups are saturated. Unsaturated monovalent hydrocarbon groups have one or more double bonds, one or more triple bonds, or combinations thereof. Preferred unsaturated monovalent hydrocarbon groups have one or two double bonds or one triple bond; more preferred unsaturated monovalent hydrocarbon groups have one double bond. [0032]
  • “Pharmaceutically acceptable” means suitable for use in a human or other mammal. [0033]
  • “PGF” means a prostaglandin F analog. [0034]
  • “Prostaglandin” means a fatty acid derivative which has a variety of potent biological activities of a hormonal or regulatory nature. [0035]
  • “Protecting group” is a group that replaces the active hydrogen of a hydroxyl moiety thus preventing undesired side reaction at the hydroxyl moiety. Use of protecting groups in organic synthesis is well known in the art. Examples of protecting groups are found in Chapter 2 [0036] Protecting Groups in Organic Synthesis by Greene, T. W. and Wuts, P. G. M., 2nd ed., Wiley & Sons, Inc., 1991. Preferred protecting groups include silyl ethers, alkoxymethyl ethers, tetrahydropyranyl, tetrahydrofuranyl, esters, and substituted or unsubstituted benzyl ethers.
  • “Safe and effective amount” means a quantity of a prostaglandin high enough to provide a significant positive modification of the subject's condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio). [0037]
  • “Selective” means having a binding or activation preference for a specific receptor over other receptors which can be quantitated based upon receptor binding or activation assays. [0038]
  • “Subject” means a living, vertebrate, hair- or fur-bearing animal such as a mammal (preferably human) in need of treatment. [0039]
  • “Substituted aromatic group” means an aromatic group wherein 1 to 4 of the hydrogen atoms bonded to carbon atoms in the ring have been replaced with other substituents. Preferred substituents include: halogen atoms, cyano groups, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, aromatic groups, substituted aromatic groups, or any combination thereof. More preferred substituents include halogen atoms, monovalent hydrocarbon groups, and substituted monovalent hydrocarbon groups. Preferred substituted aromatic groups include naphthyl. The substituents may be substituted at the ortho, meta, or para position on the ring, or any combination thereof. The preferred substitution pattern on the ring is ortho or meta. The most preferred substitution pattern is ortho. [0040]
  • “Substituted carbocyclic group” means a carbocyclic group wherein 1 to 4 hydrogen atoms bonded to carbon atoms in the ring have been replaced with other substituents. Preferred substituents include: halogen atoms, cyano groups, monovalent hydrocarbon groups, monovalent heterogeneous groups, substituted monovalent hydrocarbon groups, aromatic groups, substituted aromatic groups, or any combination thereof. More preferred substituents include halogen atoms and substituted monovalent hydrocarbon groups. Carbocyclic group does not include aromatic rings. [0041]
  • “Substituted heteroaromatic group” means a heteroaromatic group wherein 1 to 4 hydrogen atoms bonded to carbon atoms in the ring have been replaced with other substituents. Preferred substituents include: halogen atoms, cyano groups, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, phenyl groups, phenoxy groups, or any combination thereof. More preferred substituents include halogen atoms, halogenated hydrocarbon groups, halogenated heterogenous groups, monovalent hydrocarbon groups, and phenyl groups. [0042]
  • “Substituted heterocyclic group” means a heterocyclic group wherein 1 to 4 hydrogen atoms bonded to carbon atoms in the ring have been replaced with other substituents. Preferred substituents include: halogen atoms, cyano groups, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, halogenated hydrocarbon groups, halogenated heterogenous groups, phenyl groups, phenoxy groups, or any combination thereof. More preferred substituents include halogen atoms and halogenated hydrocarbon groups. Substituted heterocyclic groups are not aromatic. [0043]
  • “Substituted heterogeneous group” means a heterogeneous group, wherein 1 to 4 of the hydrogen atoms bonded to carbon atoms in the chain have been replaced with other substituents. Preferred substituents include halogen atoms, hydroxy groups, alkoxy groups (e.g., methoxy, ethoxy, propoxy, butoxy, and pentoxy), aryloxy groups (e.g., phenoxy, chlorophenoxy, tolyloxy, methoxyphenoxy, benzyloxy, alkyloxycarbonylphenoxy, and acyloxyphenoxy), acyloxy groups (e.g., propionyloxy, benzoyloxy, and acetoxy), carbamoyloxy groups, carboxy groups, mercapto groups, alkylthio groups, acylthio groups, arylthio groups (e.g., phenylthio, chlorophenylthio, alkylphenylthio, alkoxyphenylthio, benzylthio, and alkyloxycarbonylphenylthio), aromatic groups (e.g., phenyl and tolyl), substituted aromatic groups (e.g., alkoxyphenyl, alkoxycarbonylphenyl, and halogenated phenyl), heterocyclic groups, heteroaromatic groups, and amino groups (e.g., amino, mono- and di-alkylamino having 1 to 3 carbon atoms, methylphenylamino, methylbenzylamino, alkanylamido groups of 1 to 3 carbon atoms, carbamamido, ureido, and guanidino). [0044]
  • “Substituted monovalent hydrocarbon group” means a monovalent hydrocarbon group wherein 1 to 4 of the hydrogen atoms bonded to carbon atoms in the chain have been replaced with other substituents. Preferred substituents include halogen atoms; halogenated hydrocarbon groups; halogenated heterogneous groups; alkyl groups (e.g., methyl, ethyl, propyl, and butyl); hydroxy groups; alkoxy groups (e.g., methoxy, ethoxy, propoxy, butoxy, and pentoxy); aryloxy groups (e.g., phenoxy, chlorophenoxy, tolyloxy, methoxyphenoxy, benzyloxy, alkyloxycarbonylphenoxy, and acyloxyphenoxy); acyloxy groups (e.g., propionyloxy, benzoyloxy, and acetoxy); carbamoyloxy groups; carboxy groups; mercapto groups; alkylthio groups; acylthio groups; arylthio groups (e.g., phenylthio, chlorophenylthio, alkylphenylthio, alkoxyphenylthio, benzylthio, and alkyloxycarbonylphenylthio); aromartic groups (e.g., phenyl and tolyl); susbstituted aromatic groups (e.g., alkoxyphenyl, alkoxycarbonylphenyl, and halogenated phenyl); heterocyclic groups; heteroaryl groups; and amino groups (e.g., amino, mono- and di-alkanylamino groups of 1 to 3 carbon atoms, methylphenylamino, methylbenzylamino, alkanylamido groups of 1 to 3 carbon atoms, carbamamido, ureido, and guanidino). [0045]
  • Prostaglandin F Analogs Used in the Invention
  • This invention relates to the use of prostaglandin F analogs (PGFs) to treat hair loss. “Treating hair loss” means arresting hair loss, reversing hair loss, or both, and promoting hair growth. Suitable PGFs for use in this invention are selected from the group consisting of PGFs having the structure: [0046]
    Figure US20020037914A1-20020328-C00003
  • and pharmaceutically acceptable salts, hydrates, and biohydrolyzable amides, esters, and imides thereof. [0047]
  • R[0048] 1 is selected from the group consisting of CO2H, C(O)NHOH, CO2R5, CH2OH, S(O)2R5, C(O)NHR5, C(O)NHS(O)2R5, and tetrazole. R5 is selected from the group consisting of monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, aromatic groups, substituted aromatic groups, carbocyclic groups, substituted carbocyclic groups, heterogeneous groups, substituted heterogeneous groups, heterocyclic groups, substituted heterocyclic groups, heteroaromatic groups, and substituted heteroaromatic groups. Preferably, R5 is selected from the group consisting of CH3, C2H5, and C3H7. Preferably, R1 is selected from the group consisting of CO2H, CO2CH3, CO2C2H5, CO2C3H7, CO2C4H9, CO2C3H7O2, and C(O)NHS(O)2R5. More preferably, R1 is selected from the group consisting of CO2H, CO2CH3, CO2C2H5, and CO2C3H7. Most preferably, R1 is selected from the group consisting of CO2H, CO2CH3, and CO2C3H7.
  • R[0049] 2 is a hydrogen atom or a lower monovalent hydrocarbon group. R2 is preferably a hydrogen atom or a methyl group.
  • R[0050] 3 and R4 are each independently selected from the group consisting of H, CH3, C2H5, OR10, SR10, and OH; with the proviso that both R3 and R4 are not OH. R10 is selected from the group consisting of a monovalent hydrocarbon group, a substituted monovalent hydrocarbon group, a heterogeneous group, a substituted heterogeneous group, a carbocyclic group, a substituted carbocyclic group, an aromatic group, a substituted aromatic group, a heteroaromatic group, and a substituted heteroaromatic group; with the proviso that R10 has 1 to 8 member atoms. Preferably, R3 and R4 are both hydrogen atoms.
  • X is selected from the group consisting of NR[0051] 6R7, OR8, SR9, S(O)R9, and S(O)2R9. Preferably, X is selected from the group consisting of NR6R7 and OR8. More preferably, X is OH.
  • R[0052] 6, R7, and R8 are each independently selected from the group consisting of hydrogen atoms, acyl groups, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, carbocyclic groups, substituted carbocyclic groups, aromatic groups, substituted aromatic groups, heteroaromatic groups, and substituted heteroaromatic groups. Preferably, R6 and R7 are selected from the group consisting of H, CH3, and C2H5. Preferably, R8 is selected from the group consisting of H, CH3, C2H5, and C3H7.
  • R[0053] 9 is selected from the group consisting of monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, carbocyclic groups, substituted carbocyclic groups, heterocyclic groups, substituted heterocyclic groups, aromatic groups, substituted aromatic groups, heteroaromatic groups, and substituted heteroaromatic groups. Preferably, R9 is selected from the group consisting of CH3, and C2H5.
  • Y is selected from the group consisting of an oxygen atom, a divalent hydrocarbon group, a sulfur-containing moiety, and a nitrogen-containing group. The divalent hydrocarbon group has the formula (CH[0054] 2)n, wherein n is an integer with a value of 0 to 3. Preferably, n is 0, 1, or 2; more preferably, n is 1.
  • The sulfur-containing moiety for Y is selected from the group consisting of a sulfur atom, S(O), and S(O)[0055] 2. When Y is a sulfur-containing moiety, it preferably is a sulfur atom.
  • The nitrogen-containing group for Y has the formula NR[0056] 11. R11 is selected from the group consisting of a hydrogen atom, an acyl group, a monovalent hydrocarbon group, a substituted monovalent hydrocarbon group, a heterogeneous group, a substituted heterogeneous group, a carbocyclic group, a substituted carbocyclic group, a heterocyclic group, a substituted heterocyclic group, an aromatic group, a substituted aromatic group, a heteroaromatic group, and a substituted heteroaromatic group. Preferably R11 is H or CH3.
  • Z is selected from the group consisting of a carbocyclic group, a substituted carbocyclic group, a heterocyclic group, a substituted heterocyclic group, an aromatic group, a substituted aromatic group, a heteroaromatic group, and a substituted heteroaromatic group. Preferably Z is selected from the group consisting of a monocyclic carbocyclic group, a substituted monocyclic carbocyclic group, a monocyclic heterocyclic group, a substituted monocyclic heterocyclic group, a monocyclic aromatic group, a substituted monocyclic aromatic group, a monocyclic heteroaromatic group, and a substituted monocyclic heteroaromatic group. More preferably, Z is selected from the group consisting of a monocyclic aromatic group, a substituted monocyclic aromatic group, a monocyclic heteroaromatic group, and a substituted monocyclic heteroaromatic group. Most preferably, Z is thienyl or phenyl. [0057]
  • Optical isomers, diastereomers, and enantiomers of the structure described above are also suitable for use in this invention. At all stereocenters where stereochemistry is not defined (i.e., C11, C12, C15, and C16), both epimers are envisioned. [0058]
  • Examples of suitable PGF's having the formula above wherein Y is selected from the group consisting of NR[0059] 11, S, S(O), and S(O)2 include:
  • 13,14-dihydro-16-(3-methylphenylthio)-16-tetranor Prostaglandin F[0060] 1α methyl ester;
  • 13,14-dihydro-16-(3-methylphenylthio)-16-tetranor Prostaglandin F[0061] 1α;
  • 3,14-dihydro-16-(3-fluorophenylthio)-16-tetranor Prostaglandin F[0062] 1α;
  • 13,14-dihydro-16-(3-fluorophenylthio)-16-tetranor Prostaglandin F[0063] 1α methyl ester;
  • 13,14-dihydro-16-(3-fluorophenylthio)-16-tetranor Prostaglandin F[0064] 1α isopropyl ester;
  • 13,14-dihydro-16-(2,6-difluorophenylthio)-16-tetranor Prostaglandin F[0065] 1α methyl ester;
  • 13,14-dihydro-16-(3,5-difluorophenylthio)-16-tetranor Prostaglandin F[0066] 1α;
  • 13,14-dihydro-16-(2-methylphenylthio)-16-tetranor Prostaglandin F[0067] 1α methyl ester;
  • 13,14-dihydro-16-(4-methylphenylthio)-16-tetranor Prostaglandin F[0068] 1α methyl ester;
  • 13,14-dihydro-16-(4-methylphenylthio)-16-tetranor Prostaglandin F[0069] 1α;
  • 13,14-dihydro-16-(2-fluorophenylthio)-16-tetranor Prostaglandin F[0070] 1α methyl ester;
  • 13,14-dihydro-16-(2-fluorophenylthio)-16-tetranor Prostaglandin F[0071] 1α;
  • 13,14-dihydro-15-methyl-16-(3-fluorophenylthio)-16-tetranor Prostaglandin F[0072] 1α methyl ester;
  • 13,14-dihydro-15-methyl-16-(3-fluorophenylthio)-16-tetranor Prostaglandin F[0073] 1α;
  • 13,14-dihydro-15-methyl-16-(2-methylphenylthio)-16tetranor Prostaglandin F[0074] 1α methyl ester;
  • 13,14-dihydro-15-methyl-16-(2-methylphenylthio)-16-tetranor Prostaglandin F[0075] 1α;
  • 13,14-dihydro-16-(3-fluorophenylsulfonyl)-16-tetranor Prostaglan din F[0076] 1α;
  • 13,14-dihydro-16-(3-methylphenylatino)-16-tetranor prostaglandin F[0077] 1α methyl ester;
  • 13,14-dihydro-16-(3-methylphenylamino)-16-tetranor prostaglandin F[0078] 1α;
  • 13,14-dihydro-16-(2-methylphenylamino)-16-tetranor prostaglandin F[0079] 1α methyl ester;
  • 13,14-dihydro-16-(2-methylphenylamino)-16-tetranor prostaglandin F[0080] 1α;
  • 13,14-dihydro-16-(2-fluorophenylthio)-16-tetranor prostaglandin F[0081] 1α 1-hydroxamic acid;
  • 13,14-dihydro-16-(3-chlorophenylamino)-16-tetranor prostaglandin F[0082] 1α 1-hydroxamic acid;
  • 13,14-dihydro-16-(3-trifluoromethylphenylthio)-16-tetranor Prostaglandin F[0083] 1α methyl ester;
  • 13,14-dihydro-16-(3-trifluoromethylphenylthio)-16-tetranor Prostaglandin F[0084] 1α;
  • 13,14-dihydro-16-(3-trifluoromethylphenylthio)-16-tetranor prostaglandin F[0085] 1α 1-hydroxamic acid;
  • 13,14-dihydro-16-(phenylthio)-16-tetranor Prostaglandin F[0086] 1α methyl ester;
  • 13,14-dihydro-16-(phenylthio)-16-tetranor Prostaglandin F[0087] 1α isopropyl ester;
  • 13,14-dihydro-15-methyl-16-(phenylthio)-16-tetranor Prostaglandin F[0088] 1α methyl ester;
  • 13,14-dihydro-15-methyl-16-(phenylthio)-16-tetranor Prostaglandin F[0089] 1α;
  • 13,14-dihydro-16-(phenylamino)-16-tetranor prostaglandin F[0090] 1α methyl ester;
  • 13,14-dihydro-16-(phenylamino)-16-tetranor prostaglandin F[0091] 1α;
  • 13,14-dihydro-16-(2-thienylthio)-16-tetranor prostaglandin F[0092] 1α methyl ester;
  • 13,14-dihydro-16-(2-thienylthio)-16-tetranor prostaglandin F[0093] 1α;
  • 13,14-dihydro-16-(1-napthylthio)-16-tetranor Prostaglandin F[0094] 1α isopropyl ester;
  • 13,14-dihydro-16-(1-napthylthio)-16-tetranor Prostaglandin F[0095] 1α; and
  • 13,14-dihydro-15-butoxy-15-dehydroxy-16-(phenylthio)-16-tetranor prostaglandin F[0096] 1α methyl ester.
  • Examples of suitable PGF's having the formula above wherein Y is a divalent hydrocarbon group include: [0097]
  • 13,14-dihydro-17-(2,4-difluorophenyl)-17-trinor prostaglandin F[0098] 1α methyl ester;
  • 13,14-dihydro-17-(2,4-difluorophenyl)-17-trinor prostaglandin F[0099] 1α;
  • [0100] 13,14-dihydro-17-(2-fluorophenyl)-17-trinor prostaglandin F1α methyl ester;
  • 13,14-dihydro-17-(2-fluorophenyl)-17-trinor prostaglandin F[0101] 1α;
  • [0102] 13,14-dihydro-1 7-(3-fluorophenyl)-17-trinor prostaglandin F1α methyl ester;
  • 13,14-dihydro-17-(3-fluorophenyl)-17-trinor prostaglandin F[0103] 1α;
  • [0104] 13,14-dihydro-17-(4-fluorophenyl)-17-trinor prostaglandin F1α methyl ester;
  • 13,14-dihydro-17-(4-fluorophenyl)-17-trinor prostaglandin F[0105] 1α;
  • 13,14-dihydro-17-(2-methoxyphenyl)-17-trinor prostaglandin F[0106] 1α methyl ester;
  • 13,14-dihydro-17-(2-methoxyphenyl)-17-trinor prostaglandin F[0107] 1α;
  • 13,14-dihydro-17-(3-methoxyphenyl)-17-trinor prostaglandin F[0108] 1α methyl ester;
  • 13,14-dihydro-17-(3-methoxyphenyl)-17-trinor prostaglandin F[0109] 1α;
  • 13,14-dihydro-17-(4-methoxyphenyl)-17-trinor prostaglandin F[0110] 1α methyl ester;
  • 13,14-dihydro-1 7-(4-methoxyphenyl)-17-trinor prostaglandin F[0111] 1α;
  • 13,14-dihydro-17-(3,5-difluorophenyl)-17-trinor prostaglandin F[0112] 1α isopropyl ester;
  • 13,14-dihydro-18-(2-thienyl)-18-dinor prostaglandin F[0113] 1α methyl ester;
  • 13,14-dihydro-18-(2-thienyl)-18-dinor prostaglandin F[0114] 1α isopropyl ester;
  • 13,14-dihydro-17-((2-trifluoromethyl)phenyl)-17-trinor prostaglandin F[0115] 1α methyl ester;
  • 13,14-dihydro-17-((2-trifluoromethyl)phenyl)-17-trinor prostaglandin F[0116] 1α;
  • 13,14-dihydro-17-((3-trifluoromethyl)phenyl)-17-trinor prostaglandin F[0117] 1α methyl ester;
  • 13,14-dihydro-17-((3-trifluoromethyl)phenyl)-17-trinor prostaglandin F[0118] 1α;
  • 13,14-dihydro-17-((4-trifluoromethyl)phenyl)-17-trinor prostaglandin F[0119] 1α methyl ester;
  • 13,14-dihydro-17-((4-trifluoromethyl)phenyl)-17-trinor prostaglandin F[0120] 1α;
  • 13,14-dihydro-17-(2-methylphenyl)-17-trinor prostaglandin F[0121] 1α methyl ester;
  • 13,14-dihydro-17-(2-methylphenyl)-17-trinor prostaglandin F[0122] 1α;
  • 13,14-dihydro-17-(3-methylphenyl)-17-trinor prostaglandin F[0123] 1α methyl ester;
  • 13,14-dihydro-17-(3-methylphenyl)-17-trinor prostaglandin F[0124] 1α;
  • 13,14-dihydro-17-(4-methylphenyl)-17-trinor prostaglandin F[0125] 1α methyl ester; and
  • 13,14-dihydro-17-(4-methylphenyl)-17-trinor prostaglandin F[0126] 1α.
  • Examples of suitable PGF's having the formula above wherein Y is an oxygen atom include: [0127]
  • 13,14-dihydro-16,16-dimethyl-16-(2-fluorophenoxy)-16-tetranor prostaglandin F[0128] 1α;
  • 13,14-dihydro-16,16-dimethyl-16-(2-methylphenoxy)-16-tetranor Prostaglandin F[0129] 1α;
  • 13,14-dihydro-16,16-dimethyl-16-(2,3 difluorophenoxy)-16-tetranor Prostaglandin F[0130] 1α;
  • 13,14-dihydro-16-(2,5 difluorophenoxy)-16-tetranor Prostaglandin F[0131] 1α;
  • 13,14-dihydro-16-(3-fluoro-5-trifluoromethyl phenoxy)-16-tetranor Prostaglandin F[0132] 1α isopropyl ester;
  • 13,14-dihydro-16,16-dimethyl-16-(4-chlorophenoxy)-16-tetranor Prostaglandin F[0133] 1α;
  • 13,14-dihydro-16-methyl-16-(3-chlorophenoxy)-16-tetranor Prostaglandin F[0134] 1α isopropyl ester;
  • 13,14-dihydro-1[0135] 6-isopropyl-16-(2-fluorophenoxy)-16-tetranor prostaglandin F1α;
  • 13,14-dihydro-16-ethyl-1 6-(2-methylphenoxy)-1 6-tetranor Prostaglandin F[0136] 1α isopropyl ester;
  • 13,14-dihydro-16-(hydroxymethyl)-16-phenoxy-16-tetranor Prostaglandin F[0137] 1α;
  • 13,14-dihydro-16-methyl-16-(4-ethylphenoxy)-16-tetranor Prostaglandin F[0138] 1α;
  • 13,14-dihydro-16-methyl-16-(3-chlorophenoxy)-16-tetranor Prostaglandin F[0139] 1α methyl ester;
  • 13,14-dihydro-16-methyl-16-(4-phenylphenoxy)-16-tetranor Prostaglandin F[0140] 1α isopropy ester;
  • 13,14-dihydro-16,16-dimethyl-16-(4-phenoxyphenoxy)-16-tetranor Prostaglandin F[0141] 1α isopropyl ester;
  • 13,14-dihydro-16,16-dimethyl-16-(2-fluorophenoxy)-16-tetranor Prostaglandin F[0142] 1α hydroxamic acid;
  • 13,14-dihydro-16-methyl-16-(3-chlorophenoxy)-16-tetranor Prostaglandin F[0143] 1α 1-hydroxamic acid;
  • 13,14-dihydro-16-methoxymethyl-16-(2,3-difluorophenoxy)-16-tetranor Prostaglandin F[0144] 1α 1-hydroxamic acid;
  • 13,14-dihydro-16-phenoxy-16-tetranor Prostaglandin F[0145] 1α methanesulfonamide;
  • 13,14-dihydro-15-fluoro-16-(2-fluorophenoxy)-16-tetranor Prostaglandin F[0146] 1α methyl ester;
  • 13,14-dihydro-15-methyl-16,16-dimethyl-16-(2-fluorophenoxy)-16-tetranor Prostaglandin F[0147] 1α;
  • 13,14-dihydro-15-fluoro-16-(2,3-difluorophenoxy)-16-tetranor Prostaglandin F[0148] 1α 1-hydroxamic acid;
  • 13,14-dihydro-15-methylthio-15-dehydroxy-16-(2-methylphenoxy)-16-tetranor Prostaglandin F[0149] 1α;
  • 13,14-dihydro-15-methylthio-15-dehydroxy-16-methyl-16-(2-methylphenoxy) 16-tetranor Prostaglandin Floe 1-hydroxamic acid; [0150]
  • 13,14-dihydro-15-methoxy-16,16-dimethyl-16-(2-fluorophenoxy)-16-tetranor Prostaglandin F[0151] 1α 1-hydroxamic acid;
  • 13,14-dihydro-15-ethoxy-15-dehydroxy-16-phenoxy-16-tetranor Prostaglandin F[0152] 1α isopropyl ester;
  • 13,14-dihydro-15-sulfonylmethyl-15-dehydroxy-16-methyl-16-(2-methylphenoxy)-16-tetranor Prostaglandin F[0153] 1α methyl ester;
  • 13,14-dihydro-15-sulfoxylmethyl-15-dehydroxy-16-methyl-16-(2-methylphenoxy)-16-tetranor Prostaglandin F[0154] 1α methyl ester;
  • 13,14-dihydro-15-methyl-15-methylamino-15-dehydroxy-16,16-dimethyl-16-(2-fluorophenoxy)-16-tetranor Prostaglandin F[0155] 1α methyl ester;
  • 13,14-dihydro-15-methyl-15-methylamino-15-dehydroxy-16-methyl-16-(2-methylphenoxy)-16-tetranor Prostaglandin F[0156] 1α 1-hydroxamic acid;
  • 13,14-dihydro-15-methyl-15-(N,N-dimethylamino)-16-ethyl-16-(2-fluorophenoxy)-16-tetranor Prostaglandin F[0157] 1α isopropyl ester; and
  • 13,14-dihydro-16(2,6-difluorophenoxy)-16-tetranor Prostaglandin F[0158] 1α glyceryl ester.
  • Suitable PGF's are known in the art. Examples of suitable PGF's and methods for their preparation are disclosed in International Published Patent Application Numbers WO 99/12895A1, WO 99/12896A1, and WO 99/12899A1, and in U.S. Pat. No. 5,977,173. [0159]
  • Compositions of the Invention
  • This invention further relates to a composition for treating hair loss. The composition comprises A) the PGF described above and B) a carrier. The composition may further comprise C) one or more optional activity enhancers. The composition can be a pharmaceutical or cosmetic composition, administered for treatment or prophylaxis of hair loss. Standard pharmaceutical formulation techniques are used, such as those disclosed in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa. (1990). [0160]
  • The composition further comprises component B) a carrier. “Carrier” means one or more compatible substances that are suitable for administration to a mammal. Carrier includes solid or liquid diluents, hydrotopes, surface-active agents, and encapsulating substances. “Compatible” means that the components of the composition are capable of being commingled with the PGF's, and with each other, in a manner such that there is no interaction which would substantially reduce the efficacy of the composition under ordinary use situations. Carriers must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the mammal being treated. The carrier can be inert, or it can possess pharmaceutical benefits, cosmetic benefits, or both. [0161]
  • The choice of carrier for component B) depends on the route by which A) the PGF will be administered and the form of the composition. The composition may be in a variety of forms, suitable, for example, for systemic administration (e.g., oral, rectal, nasal, sublingual, buccal, or parenteral) or topical administration directly to the locus of desired hair growth (e.g., local application on the skin, ocular, liposome delivery systems, or iontophoresis). Topical administration is preferred. [0162]
  • Carriers for systemic administration typically comprise one or more ingredients selected from the group consisting of a) diluents, b) lubricants, c) binders, d) disintegrants, e) colorants, f) flavors, g) sweeteners, h) antioxidants, j) preservatives, k) glidants, m) solvents, n) suspending agents, o) surfactants, combinations thereof, and others. [0163]
  • Ingredient a) is a diluent. Suitable diluents include sugars such as glucose, lactose, dextrose, and sucrose; polyols such as propylene glycol; calcium carbonate; sodium carbonate; glycerin; mannitol; and sorbitol. [0164]
  • Ingredient b) is a lubricant. Suitable lubricants are exemplified by solid lubricants including silica, talc, stearic acid and its magnesium salts and calcium salts, calcium sulfate; and liquid lubricants such as polyethylene glycol and vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma. [0165]
  • Ingredient c) is a binder. Suitable binders include polyvinylpyrrolidone; magnesium aluminum silicate; starches such as corn starch and potato starch; gelatin; tragacanth; and cellulose and its derivatives, such as ethyl cellulose, methylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, and sodium carboxymethylcellulose; carbomer; providone; acacia; guar gum; and xanthan gum. [0166]
  • Ingredient d) is a disintegrant. Suitable disintegrants include agar, alginic acid and the sodium salt thereof, effervescent mixtures, croscarmelose, crospovidone, sodium carboxymethyl starch, sodium starch glycolate, clays, and ion exchange resins. [0167]
  • Ingredient e) is a colorant such as an FD&C dye. [0168]
  • Ingredient f) is a flavor such as menthol, peppermint, and fruit flavors. [0169]
  • Ingredient g) is a sweetener such as aspartame and saccharin. [0170]
  • Ingredient h) is an antioxidant such as butylated hydroxyanisole, butylated hydroxytoluene, and vitamin E. [0171]
  • Ingredient j) is a preservative such as phenol, alkyl esters of parahydroxybenzoic acid, benzoic acid and the salts thereof, boric acid and the salts thereof, sorbic acid and the salts thereof, chorbutanol, benzyl alcohol, thimerosal, phenylmercuric acetate and nitrate, nitromersol, benzalkonium chloride, cetylpyridinium chloride, methyl paraben, and propyl paraben. Particularly preferred are the salts of benzoic acid, cetylpyridinium chloride, methyl paraben and propyl paraben, and sodium benzoate. [0172]
  • Ingredient k) is a glidant such as silicon dioxide. [0173]
  • Ingredient m) is a solvent, such as water, isotonic saline, ethyl oleate, alcohols such as ethanol, glycerin, glycols (e.g., polypropylene glycol and polyethylene glycol), and buffer solutions (e.g., phosphate, potassium acetate, boric carbonic, phosphoric, succinic, malic, tartaric, citric, acetic, benzoic, lactic, glyceric, gluconic, glutaric and glutamic). [0174]
  • Ingredient n) is a suspending agent. Suitable suspending agents include AVICEL® RC-591 from FMC Corporation of Philadelphia, Pa. and sodium alginate. [0175]
  • Ingredient o) lecithin, polysorbate 80, sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene monoalkyl ethers, sucrose monoesters, lanolin esters, and lanolin ethers. Suitable surfactants are known in the art and commercially available, e.g., the TWEENS® from Atlas Powder Company of Wilmington, Del. [0176]
  • Compositions for parenteral administration typically comprise A) 0.1 to 10% of a PGF and B) 90 to 99.9% of a carrier comprising a) a diluent and m) a solvent. Preferably, component a) is propylene glycol and m) is ethanol or ethyl oleate. [0177]
  • Compositions for oral administration can have various dosage forms. For example, solid forms include tablets, capsules, granules, and bulk powders. These oral dosage forms comprise a safe and effective amount, usually at least 5%, and preferably from 25% to 50%, of A) the PGF. The oral dosage compositions further comprise B) 50 to 95% of a carrier, preferably 50 to 75%. [0178]
  • Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated, or multiple-compressed. Tablets typically comprise A) the PGF, and B) a carrier comprising ingredients selected from the group consisting of a) diluents, b) lubricants, c) binders, d) disintegrants, e) colorants, f) flavors, g) sweeteners, k) glidants, and combinations thereof. Preferred diluents include calcium carbonate, sodium carbonate, mannitol, lactose and cellulose. Preferred binders include starch, gelatin, and sucrose. Preferred disintegrants include alginic acid, and croscarmelose. Preferred lubricants include magnesium stearate, stearic acid, and talc. Preferred colorants are the FD&C dyes, which can be added for appearance. Chewable tablets preferably contain g) sweeteners such as aspartame and saccharin, or f) flavors such as menthol, peppermint, and fruit flavors. [0179]
  • Capsules (including time release and sustained release formulations) typically comprise A) the PGF, and B) a carrier comprising one or more a) diluents disclosed above in a capsule comprising gelatin. Granules typically comprise A) the PGF, and preferably further comprise k) glidants such as silicon dioxide to improve flow characteristics. [0180]
  • The selection of ingredients in the carrier for oral compositions depends on secondary considerations like taste, cost, and shelf stability, which are not critical for the purposes of this invention. One skilled in the art can optimize appropriate ingredients without undue experimentation. [0181]
  • The solid compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that A) the PGF is released in the gastrointestinal tract at various times to extend the desired action. The coatings typically comprise one or more components selected from the group consisting of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose, EUDRAGIT® coatings (available from Rohm & Haas G.M.B.H. of Darmstadt, Germany), waxes and shellac. [0182]
  • Compositions for oral administration can also have liquid forms. For example, suitable liquid forms include aqueous solutions, emulsions, suspensions, solutions reconstituted from non-effervescent granules, suspensions reconstituted from non-effervescent granules, effervescent preparations reconstituted from effervescent granules, elixirs, tinctures, syrups, and the like. Liquid orally administered compositions typically comprise A) the PGF and B) a carrier comprising ingredients selected from the group consisting of a) diluents, e) colorants, and f) flavors, g) sweeteners, j) preservatives, m) solvents, n) suspending agents, and o) surfactants. Peroral liquid compositions preferably comprise one or more ingredients selected from the group consisting of e) colorants, f) flavors, and g) sweeteners. [0183]
  • Other compositions useful for attaining systemic delivery of the subject compounds include sublingual, buccal and nasal dosage forms. Such compositions typically comprise one or more of soluble filler substances such as a) diluents including sucrose, sorbitol and mannitol; and c) binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose, and hydroxypropyl methyl cellulose. Such compositions may further comprise b) lubricants, e) colorants, f) flavors, g) sweeteners, h) antioxidants, and k) glidants. [0184]
  • The compositions may further comprise component C) an optional activity enhancer. Component C) is preferably selected from the group consisting of i) hair growth stimulants (other than the PGF) and ii) penetration enhancers. [0185]
  • Component i) is an optional hair growth stimulant. Component i) is exemplified by vasodilators, antiandrogens, cyclosporins, cyclosporin analogs, antimicrobials, anti-inflammatories, thyroid hormones, thyroid hormone derivatives, and thyroid hormone analogs, non-selective prostaglandin agonists or antagonists, retinoids, triterpenes, combinations thereof, and others. “Non-selective prostaglandin” agonists and antagonists differ from component A) in that they do not selectively activate the FP receptor, and they may activate other receptors. [0186]
  • Vasodilators such as potassium channel agonists including minoxidil and minoxidil derivatives such as aminexil and those described in U.S. Pat. Nos. 3,382,247, 5,756,092, 5,772,990, 5,760,043, 5,466,694, 5,438,058, 4,973,474, and cromakalin and diazoxide can be used as optional hair growth stimulants in the composition. [0187]
  • Examples of suitable antiandrogens include 5-α-reductase inhibitors such as finasteride and those described in U.S. Pat. No. 5,516,779, and in Nane et al., [0188] Cancer Research 58, “Effects of Some Novel Inhibitors of C17,20-Lyase and 5α-Reductase in vitro and in vivo and Their Potential Role in the Treatment of Prostate Cancer,” as well as cyproterone acetate, azelaic acid and its derivatives and those compounds described in U.S. Pat. No. 5,480,913, flutamide, and those compounds described in U.S. Pat. Nos. 5,411,981, 5,565,467, and 4,910,226. Antimicrobials include selenium sulfide, ketoconazole, triclocarbon, triclosan, zinc pyrithione, itraconazole, asiatic acid, hinokitiol, mipirocin and those described in EPA 0,680,745, clinacycin hydrochloride, benzoyl peroxide, benzyl peroxide and minocyclin.
  • Examples of suitable anti-inflammatories include glucocorticoids such as hydrocortisone, mometasone furoate and prednisolone, nonsteroidal anti-inflammatories including cyclooxygenase or lipoxygenase inhibitors such as those described in U.S. Pat. No. 5,756,092, and benzydamine, salicylic acid, and those compounds described in EPA 0,770,399, published May 2, 1997, WO 94/06434, published Mar. 31, 1994, and FR 2,268,523, published Nov. 21, 1975. [0189]
  • 3,5,3′-Triiodothyronine is an example of a suitable thyroid hormone. [0190]
  • Examples of suitable non-selective prostaglandin agonists and antagonists include compounds such as those described in WO 98/33497, Johnstone, published Aug. 6, 1998, WO 95/11003, Stjernschantz, published Apr. 27, 1995, JP 97-100091, Ueno and JP 96-134242, Nakamura. [0191]
  • Suitable retinoids include isotretinoin, acitretin, and tazarotene. [0192]
  • Other optional hair growth stimulants for component i) include benzalkonium chloride, benzethonium chloride, phenol, estradiol, chlorpheniramine maleate, chlorophyllin derivatives, cholesterol, salicylic acid, cysteine, methionine, red pepper tincture, benzyl nicotinate, D,L-menthol, peppermint oil, calcium pantothenate, panthenol, castor oil, prednisolone, resorcinol, chemical activators of protein kinase C, glycosaminoglycan chain cellular uptake inhibitors, inhibitors of glycosidase activity, glycosaminoglycanase inhibitors, esters of pyroglutamic acid, hexosaccharic acids or acylated hexosaccharic acids, aryl-substituted ethylenes, N-acylated amino acids, flavinoids, ascomycin derivatives and analogs, histamine antagonists such as diphenhydramine hydrochloride, triterpenes such as oleanolic acid and ursolic acid and those described in U.S. Pat. Nos. 5,529,769, 5,468,888, 5,631,282, and 5,679,705, JP 10017431, WO 95/35103, JP 09067253, WO 92/09262, JP 62093215, and JP 08193094; saponins such as those described in EP 0,558,509 to Bonte et al., published Sep. 8, 1993 and WO 97/01346 to Bonte et al, published Jan. 16, 1997, proteoglycanase or glycosaminoglycanase inhibitors such as those described in U.S. Pat. Nos. 5,015,470, 5,300,284, and 5,185,325, estrogen agonists and antagonists, pseudoterins, cytokine and growth factor promoters, analogs or inhibitors such as interleukin 1 inhibitors, interleukin-6 inhibitors, interleukin-10 promoters, and tumor necrosis factor inhibitors, vitamins such as vitamin D analogs and parathyroid hormone antagonists, Vitamin B12 analogs and panthenol, interferon agonists and antagonists, hydroxyacids such as those described in U.S. Pat. No. 5,550,158, benzophenones, and hydantoin anticonvulsants such as phenytoin, and combinations thereof. [0193]
  • Other additional hair growth stimulants are described in JP 09-157,139 to Tsuji et al., published Jun. 17, 1997; EP 0277455 A1 to Mirabeau, published Aug. 10, 1988; WO 97/05887 to Cabo Soler et al., published Feb. 20, 1997; WO 92/16186 to Bonte et al., published Mar. 13, 1992; JP 62-93215 to Okazaki et al., published Apr. 28, 1987; U.S. Pat. No. 4,987,150 to Kurono et al., issued Jan. 22, 1991; JP 290811 to Ohba et al., published Oct. 15, 1992; JP 05-286,835 to Tanaka et al., published Nov. 2, 1993, FR 2,723,313 to Greff, published Aug. 2, 1994, U.S. Pat. No. 5,015,470 to Gibson, issued May 14, 1991, U.S. Pat. No. 5,559,092, issued Sep. 24, 1996, U.S. Pat. No. 5,536,751, issued Jul. 16, 1996, U.S. Pat. No. 5,714,515, issued Feb. 3, 1998, EPA 0,319,991, published Jun. 14, 1989, EPA 0,357,630, published Oct. 6, 1988, EPA 0,573,253, published Dec. 8, 1993, JP 61-260010, published Nov. 18, 1986, U.S. Pat. No. 5,772,990, issued Jun. 30, 1998, U.S. Pat. No. 5,053, 410, issued Oct. 1, 1991, and U.S. Pat. No. 4,761,401, issued Aug. 2, 1988. [0194]
  • The most preferred activity enhancers are minoxidil and finasteride, most preferably minoxidil. [0195]
  • Component ii) is a penetration enhancer that can be added to all of the compositions for systemic administration. The amount of component ii), when present in the composition, is typically 1 to 5%. Examples of penetration enhancers include 2-methyl propan-2-ol, propan-2-ol, ethyl-2-hydroxypropanoate, hexan-2,5-diol, polyoxyethylene(2) ethyl ether, di(2-hydroxypropyl) ether, pentan-2,4-diol, acetone, polyoxyethylene(2) methyl ether, 2-hydroxypropionic acid, 2-hydroxyoctanoic acid, propan-1-ol, 1,4-dioxane, tetrahydrofuran, butan-1,4-diol, propylene glycol dipelargonate, polyoxypropylene 15 stearyl ether, octyl alcohol, polyoxyethylene ester of oleyl alcohol, oleyl alcohol, lauryl alcohol, dioctyl adipate, dicapryl adipate, di-isopropyl adipate, di-isopropyl sebacate, dibutyl sebacate, diethyl sebacate, dimethyl sebacate, dioctyl sebacate, dibutyl suberate, dioctyl azelate, dibenzyl sebacate, dibutyl phthalate, dibutyl azelate, ethyl myristate, dimethyl azelate, butyl myristate, dibutyl succinate, didecyl phthalate, decyl oleate, ethyl caproate, ethyl salicylate, isopropyl palmitate, ethyl laurate, 2-ethyl-hexyl pelargonate, isopropyl isostearate, butyl laurate, benzyl benzoate, butyl benzoate, hexyl laurate, ethyl caprate, ethyl caprylate, butyl stearate, benzyl salicylate, 2-hydroxypropanoic acid, 2-hydroxyoctanoic acid, dimethyl sulphoxide, N,N-dimethyl acetamide, N,N-dimethyl formamide, 2-pyrrolidone, 1-methyl-2-pyrrolid(one, 5-methyl-2-pyrrolidone, 1,5-dimethyl-2-pyrrolidone, 1-ethyl-2-pyrrolidone, phosphine oxides, sugar esters, tetrahydrofurfural alcohol, urea, diethyl-m-toluamide, 1-dodecylazacyloheptan-2-one, omega three fatty acids and fish oils, and combinations thereof. [0196]
  • In a preferred embodiment of the invention, the PGF's are topically administered. Topical compositions that can be applied locally to the skin may be in any form including solutions, oils, creams, ointments, gels, lotions, shampoos, leave-on and rinse-out hair conditioners, milks, cleansers, moisturizers, sprays, skin patches, and the like. Topical compositions comprise: component A) the PGF described above and component B) a carrier. The carrier of the topical composition preferably aids penetration of the PGF's into the skin to reach the environment of the hair follicle. Component B) may further comprise one or more optional components. Topical compositions preferably further comprise C) one or more of the optional activity enhancers described above. [0197]
  • The exact amounts of each component in the topical composition depend on various factors. The amount of component A) depends on the IC[0198] 50 of the PGF selected. “IC50” means inhibitory concentration 50th percentile. The amount of component A) added to the topical composition is:
  • IC 50×10−2≧% of component A)≧IC 50×10−3,
  • where IC[0199] 50 is expressed in nanomolar units. For example, if the IC50 of the PGF is 1 nM, the amount of component A) will be 0.001 to 0.01%. If the IC50 of the PGF is 10 nM, the amount of component A) will be 0.01 to 0.1%. If the IC50 of the PGF is 100 nM, the amount of component A) will be 0.1 to 1.0%. If the IC50 of the PGF is 1000 nM, the amount of component A) will be 1.0 to 10%, preferably 1.0 to 5%. If the amount of component A) is outside the ranges specified above (i.e., either higher or lower), efficacy of the treatment may be reduced. IC50 can be calculated according to the method in Reference Example 1, below. One skilled in the art can calculate IC50 without undue experimentation.
  • The topical composition preferably further comprises 1 to 20% component C), and a sufficient amount of component B) such that the amounts of components A), B), and C), combined equal 100%. The amount of B) the carrier employed in conjunction with the PGF is sufficient to provide a practical quantity of material for administration per unit dose of the compound. Techniques and compositions for making dosage forms useful in the methods of this invention are described in the following references: [0200] Modern Pharmaceutics, Chapters 9 and 10, Banker & Rhodes, eds. (1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms, 2nd Ed., (1976).
  • Component B) the carrier may comprise a single ingredient or a combination of two or more ingredients. In the topical compositions, component B) is a topical carrier. Preferred topical carriers comprise one or more ingredients selected from the group consisting of water, alcohols, aloe vera gel, allantoin, glycerin, vitamin A and E oils, mineral oil, propylene glycol, polypropylene glycol-2 myristyl propionate, dimethyl isosorbide, combinations thereof, and the like. More preferred carriers include propylene glycol, dimethyl isosorbide, and water. [0201]
  • The topical carrier may comprise one or more ingredients selected from the group consisting of q) emollients, r) propellants, s) solvents, t) humectants, u) thickeners, v) powders, and w) fragrances in addition to, or instead of, the preferred topical carrier ingredients listed above. One skilled in the art would be able to optimize carrier ingredients for the topical compositions without undue experimentation. [0202]
  • Ingredient q) is an emollient. The amount of ingredient q) in the topical composition is typically 5 to 95%. Suitable emollients include stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petrolatum, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, myristyl myristate, polydimethylsiloxane, and combinations thereof. Preferred emollients include stearyl alcohol and polydimethylsiloxane. [0203]
  • Ingredient r) is a propellant. The amount of ingredient r) in the topical composition is typically 5 to 95%. Suitable propellants include propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide, and combinations thereof. Ingredient s) is a solvent. The amount of ingredient s) in the topical composition is typically 5 to 95%. Suitable solvents include water, ethyl alcohol, methylene chloride, isopropanol, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethylsulfoxide, dimethyl formamide, tetrahydrofuran, and combinations thereof. Preferred solvents include ethyl alcohol. [0204]
  • Ingredient t) is a humectant. The amount of ingredient t) in the topical composition is typically 5 to 95%. Suitable humectants include glycerin, sorbitol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, gelatin, and combinations thereof. Preferred humectants include glycerin. [0205]
  • Ingredient u) is a thickener. The amount of ingredient u) in the topical composition is typically 0 to 95%. [0206]
  • Ingredient v) is a powder. The amount of ingredient v) in the topical composition is typically 0 to 95%. Suitable powders include chalk, talc, fullers earth, kaolin, starch, gums, colloidal silicon dioxide, sodium polyacrylate, tetra alkyl ammonium smectites, trialkyl aryl ammonium smectites, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate, and combinations thereof. [0207]
  • Ingredient w) is a fragrance. The amount of ingredient w) in the topical composition is typically 0.001 to 0.5%, preferably 0.001 to 0.1%. [0208]
  • Component C) the optional activity enhancer is as described above. Any of the i) hair growth stimulants and ii) penetration enhancers may be added to the topical compositions. Preferably, the topical composition comprises 0.01 to 15% of component i) the optional hair growth stimulant. More preferably, the composition comprises 0.1 to 10%, and most preferably 0.5 to 5% of component i). Preferably, the topical composition comprises 1 to 5% of component ii). [0209]
  • In an alternative embodiment of the invention, topical pharmaceutical compositions for ocular administration are prepared by conventional methods. Topical pharmaceutical compositions for ocular administration typically comprise A) a PGF, B) a carrier, such as purified water, and one or more ingredients selected from the group consisting of y) sugars such as dextrans, particularly dextran 70, z) cellulose or a derivative thereof, aa) a salt, bb) disodium EDTA (Edetate disodium), and cc) a pH adjusting additive. [0210]
  • Examples of z) cellulose derivatives suitable for use in the topical pharmaceutical composition for ocular administration include sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, and hydroxypropylmethylcellulose. Hydroxypropylmethylcellulose is preferred. [0211]
  • Examples of aa) salts suitable for use in the for use in the topical pharmaceutical composition for ocular administration include sodium chloride, potassium chloride, and combinations thereof. [0212]
  • Examples of cc) pH adjusting additives include HCl or NaOH in amounts sufficient to adjust the pH of the topical pharmaceutical composition for ocular administration to 7.2-7.5. [0213]
  • This invention further relates to a method for darkening hair, thickening hair, and reversing hair graying. The method comprises applying the topical composition for treating hair loss to hair, to skin in the locus of hair, or both. For example, the topical composition may be applied to hair growing on the scalp or eyelashes. The topical composition can be, for example, a cosmetic composition prepared as described above. An example of a composition that may be applied to eyelashes is a mascara. The prostaglandin may be added to mascara compositions known in the art, such as the mascara described in U.S. Pat. No. 5,874,072, which is hereby incorporated by reference. The mascara comprises dd) a water-insoluble material, ee) a water-soluble, film-forming polymer, ff) a wax, o) a surfactant, gg) a pigment, and s) a solvent. [0214]
  • Ingredient dd) is a water-insoluble material selected from the group consisting of acrylate copolymers; styrene/acrylate/methacrylate copolymers; acrylic latex; styrene/acrylic ester copolymer latex; polyvinylacetate latex; vinyl acetate/ethylene copolymer latex; styrene/butadiene copolymer latex; polyurethane latex; butadiene/acrylonitrile copolymer latex; styrene/acrylate/acrylonitrile copolymer latex; and mixtures thereof, wherein the acrylate copolymers, and the styrene/acrylate/methacrylate copolymers additionally comprise ammonia, propylene glycol, a preservative and a surfactant. [0215]
  • Ingredient ee) is a water-soluble, film-forming polymer. Ingredient ee) is selected from the group consisting of vinyl alcohol/poly(alkyleneoxy)acrylate, vinyl alcohol/vinyl acetate/poly-(alkyleneoxy)acrylate, polyethylene oxide, polypropylene oxide, acrylates/octyl-acrylamide copolymers and mixtures thereof. [0216]
  • Ingredient ff) is a wax. “Wax” means a lower-melting organic mixture or compound of high molecular weight, solid at room temperature and generally similar in composition to fats and oils except that they contain no glycerides. Some are hydrocarbons, others are esters of fatty acids and alcohols. Waxes useful in this invention are selected from the group consisting of animal waxes, vegetable waxes, mineral waxes, various fractions of natural waxes, synthetic waxes, petroleum waxes, ethylenic polymers, hydrocarbon types such as Fischer-Tropsch waxes, silicone waxes, and mixtures thereof wherein the waxes have a melting point between 55 and 100° C. [0217]
  • Ingredient o) is surfactant, as described above. Ingredient o) in the mascara is preferably a surfactant having an HLB from 3 to 15. Suitable surfactants include those disclosed in the [0218] C.T.F.A. Cosmetic Ingredient Handbook, pp.587-592 (1992); Remington's Pharmaceutical Sciences, 15th Ed. pp. 335-337 (1975); and McCutcheon's Volume 1, Emulsifiers & Detergents, North American Edition, pp. 236-239 (1994).
  • Ingredient gg) is a pigment. Suitable pigments include inorganic pigments, organic lake pigments, pearlescent pigments, and mixtures thereof. Inorganic pigments useful in this invention include those selected from the group consisting of rutile or anatase titanium dioxide, coded in the Color Index under the reference CI 77,891; black, yellow, red and brown iron oxides, coded under references CI 77,499, 77,492 and, 77,491; manganese violet (CI 77,742); ultramarine blue (CI 77,007); chromium oxide (CI 77,288); chromium hydrate (CI 77,289); and ferric blue (CI 77,510) and mixtures thereof. [0219]
  • The organic pigments and lakes useful in this invention include those selected from the group consisting of D&C Red No. 19 (CI 45,170), D&C Red No. 9 (CI 15,585), D&C Red No. 21 (CI 45,380), D&C Orange No. 4 (CI 15,510), D&C Orange No. 5 (CI 45,370), D&C Red No. 27 (CI 45,410), D&C Red No. 13 (CI 15,630), D&C Red No. 7 (CI 15,850), D&C Red No. 6 (CI 15,850), D&C Yellow No. 5 (CI 19,140), D&C Red No. 36 (CI 12,085), D&C Orange No. 10 (CI 45,425), D&C Yellow No. 6 (CI 15,985), D&C Red No. 30 (CI 73,360), D&C Red No. 3 (CI 45,430) and the dye or lakes based on Cochineal Carmine (Cl 75,570) and mixtures thereof. [0220]
  • The pearlescent pigments useful in this invention include those selected from the group consisting of the white pearlescent pigments such as mica coated with titanium oxide, bismuth oxychloride, colored pearlescent pigments such as titanium mica with iron oxides, titanium mica with ferric blue, chromium oxide and the like, titanium mica with an organic pigment of the above-mentioned type as well as those based on bismuth oxychloride and mixtures thereof. [0221]
  • Ingredient s) is a solvent described above, preferably water. [0222]
  • The amount of A) the PGF added to the mascara is as described above for topical compositions. [0223]
  • The PGF's may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines. A preferred formulation for topical delivery of the present compounds uses liposomes as described in Dowton et al., “Influence of Liposomal Composition on Topical Delivery of Encapsulated Cyclosporin A: I. An in vitro Study Using Hairless Mouse Skin”, S.T.P. Pharma Sciences, Vol. 3, pp. 404-407 (1993); Wallach and Philippot, “New Type of Lipid Vesicle: Novasome®”, [0224] Liposome Technology, Vol. 1, pp. 141-156 (1993); Wallach, U.S. Pat. No. 4,911,928, assigned to Micro-Pak, Inc., issued Mar. 27, 1990; and Weiner et al., U.S. Pat. No. 5,834,014, assigned to The University of Michigan and Micro-Pak, Inc., issued November 10, 1998 (with respect to Weiner et al., with a compound as described herein administered in lieu of, or in addition to, minoxidil).
  • The PGF's may also be administered by iontophoresis. See, e.g., Internet site www.unipr.it/arpa/dipfarm/erasmus/erasm14.html; Banga et al., “Hydrogel-based lontotherapeutic Delivery Devices for Transdermal Delivery of Peptide/Protein Drugs”, Pharm. Res., Vol. 10 (5), pp. 697-702 (1993); Ferry, “Theoretical Model of Iontophoresis Utilized in Transdermal Drug Delivery”, Pharmaceutical Acta Helvetiae, Vol 70, pp. 279-287 (1995); Gangarosa et al., “Modern Iontophoresis for Local Drug Delivery”, Int. J. Pharm, Vol. 123, pp. 159-171 (1995); Green et al., “Iontophoretic Delivery of a Series of Tripeptides Across the Skin in vitro”, Pharm. Res., Vol 8, pp. 1121-1127 (1991); Jadoul et al., “Quantification and Localization of Fentanyl and TRH Delivered by Iontophoresis in the Skin”, Int. J. Pharm., Vol. 120, pp. 221-8 (1995); O'Brien et al., “An Updated Review of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy”, Drugs, Vol. 37, pp. 233-309 (1989); Parry et al., “Acyclovir Biovailability in Human Skin”, J. Invest. Dermatol., Vol. 98 (6), pp. 856-63 (1992); Santi et al., “Drug Reservoir Composition and Transport of Salmon Calcitonin in Transdermal lontophoresis”, Pharm. Res., Vol 14 (1), pp. 63-66 (1997); Santi et al., “Reverse Iontophoresis—Parameters Determining Electroosmotic Flow: I. pH and Ionic Strength”, J. Control. Release, Vol. 38, pp. 159-165 (1996); Santi et al., “Reverse Iontophoresis—Parameters Determining Electroosmotic Flow: II. Electrode Chamber Formulation”, J. Control. Release, Vol. 42, pp. 29-36 (1996); Rao et al., “Reverse lontophoresis: Noninvasive Glucose Monitoring in vivo in Humans”, Pharm. Res., Vol. 12 (12), pp. 1869-1873 (1995); Thysman et al., “Human Calcitonin Delivery in Rats by lontophoresis”, J. Pharm. Pharmacol., Vol. 46, pp. 725-730 (1994); and Volpato et al., “Iontophoresis Enhances the Transport of Acyclovir through Nude Mouse Skin by Electrorepulsion and Electroosmosis”, Pharm. Res., Vol. 12 (11), pp. 1623-1627 (1995). [0225]
  • The PGF's may be included in kits comprising a PGF, a systemic or topical composition described above, or both; and information, instructions, or both that use of the kit will provide treatment for hair loss in mammals (particularly humans). The information and instructions may be in the form of words, pictures, or both, and the like. In addition or in the alternative, the kit may comprise a PGF, a composition, or both; and information, instructions, or both, regarding methods of application of the PGF or composition, preferably with the benefit of treating hair loss in mammals. [0226]
  • In all of the foregoing compositions, and for all routes of administration, the PGF's can be used alone or in combinations of two or more PGF's. The compositions may further comprise additional drugs or excipients as appropriate for the indication. [0227]
  • Methods of the Invention
  • This invention further relates to a method for treating hair loss in mammals. The method comprises administering to a mammal (preferably a human) suffering from hair loss, a PGF described above. For example, a mammal diagnosed with alopecia including male pattern baldness and female pattern baldness can be treated by the methods of this invention. Preferably, a systemic or topical composition comprising A) the PGF and B) a carrier is administered to the mammal. More preferably, the composition is a topical composition comprising A) the PGF, B) the carrier, and C) an optional activity enhancer. [0228]
  • The dosage of the PGF administered depends on the method of administration. For systemic administration, (e.g., oral, rectal, nasal, sublingual, buccal, or parenteral), typically, 0.5 mg to 300 mg, preferably 0.5 mg to 100 mg, more preferably 0.1 mg to 10 mg, of a PGF described above is administered per day. These dosage ranges are merely exemplary, and daily administration can be adjusted depending on various factors. The specific dosage of the PGF to be administered, as well as the duration of treatment, and whether the treatment is topical or systemic are interdependent. The dosage and treatment regimen will also depend upon such factors as the specific PGF used, the treatment indication, the efficacy of the compound, the personal attributes of the subject (such as, for example, weight, age, sex, and medical condition of the subject), compliance with the treatment regimen, and the presence and severity of any side effects of the treatment. [0229]
  • For topical administration (e.g., local application on the skin, ocular, liposome delivery systems, or iontophoresis), the topical composition is typically administered once per day. The topical compositions are administered daily for a relatively short amount of time (i.e., on the order of weeks). Generally, 6 to 12 weeks is sufficient. The topical compositions are preferably leave-on compositions. In general, the topical composition should not be removed for at least several hours after administration. [0230]
  • In addition to the benefits in treating hair loss, the inventors have surprisingly found that the PGF's in the compositions and methods of this invention also darken and thicken hair and may reverse hair graying. [0231]
  • EXAMPLES
  • These examples are intended to illustrate the invention to those skilled in the art and should not be interpreted as limiting the scope of the invention set forth in the claims. [0232]
  • Reference Example 1 Radioligand Binding Assay
  • IC[0233] 50 of a PGF can be determined relative to PGF using the Radioligand Binding Assay. As a control, the IC50 for PGF itself should be no lower than 1.0 nM and no higher than 5.0 nM.
  • In this assay, COS-7 cells are transiently transfected with the hFP recombinant plasmid using LipofectAlNE Reagent. Forty-eight hours later, the tranfected cells are washed with Hank's Balanced Salt Solution (HBSS, without CaCl[0234] 2, MgCl2, MgSO4, or phenol red). The cells are detached with versene, and HBSS is added. The mixture is centrifuged at 200g for 10 minutes, at 4° C. to pellet the cells. The pellet is resuspended in Phosphate-Buffered Saline-EDTA buffer (PBS; 1 mM EDTA; pH 7.4; 4° C.). The cells are disrupted by nitrogen cavitation (Parr model 4639), at 800 psi, for 15 minutes at 4° C. The mixture is centrifuged at 1000 g for 10 minutes at 4° C. The supernatant is centrifuged at 100,000 g for 60 minutes at 4° C. The pellet is resuspended to 1 mg protein/mL TME buffer (50 mM Tris; 10 mM MgCl2; 1 mM EDTA; pH 6.0; 4° C.) based on protein levels measured using the Pierce BCA Protein Assay kit. The homogenate is mixed for 10 seconds using a Kinematica POLYTRON® (available from KINEMATICA AG, Luzernerstrassel47A CH-6014 Littau, Switzerland). The membrane preparations are then stored at -80° C., until thawed for assay use.
  • The receptor competition binding assays are developed in a 96 well format. Each well contains 100 g of hFP membrane, 5 nM (3 H) PGF2, and the various competing compounds in a total volume of 200 L. The plates are incubated at 23° C. for 1 hour. The incubation is terminated by rapid filtration using the Packard Filtermate 196 harvester through Packard UNIFILTER® GFIB filters (available from Packard Instrument Co., Inc. of Downers Grove Ill.) pre-wetted with TME buffer. The filter is washed four times with TME buffer. Packard Microscint 20, a high efficiency liquid scintillation cocktail, is added to the filter plate wells and the plates remain at room temperature for three hours prior to counting. The plates are read on a Packard TOPCOUNT® Microplate Scintillation Counter (also available from Packard Instrument Co., Inc.) [0235]
  • Reference Example 2 Telogen Conversion Assay
  • PGF's are tested for their potential to grow hair using the Telogen Conversion Assay. The Telogen Conversion Assay measures the potential of a PGF to convert mice in the resting stage of the hair growth cycle (“telogen”), to the growth stage of the hair growth cycle (“anagen”). [0236]
  • Without intending to be limited by theory, there are three principal phases of the hair growth cycle: anagen, catagen, and telogen. It is believed that there is a longer telogen period in C3H mice (Harlan Sprague Dawley, Inc., Indianapolis, Ind.) from approximately 40 days of age until about 75 days of age, when hair growth is synchronized. It is believed that after 75 days of age, hair growth is no longer synchronized. Wherein about 40 day-old mice with dark fur (brown or black) are used in hair growth experiments, melanogenesis occurs along with hair (fur) growth wherein the topical application of hair growth inducers are evaluated. The Telogen Conversion Assay herein is used to screen PGF's for potential hair growth by measuring melanogenesis. [0237]
  • Three groups of 44 day-old C3H mice are used: a vehicle control group, a positive control group, and a test PGF group, wherein the test PGF group is administered a PGF used in the method of this invention. The length of the assay is 24 days with 15 treatment days (wherein the treatment days occur Mondays through Fridays). Day 1 is the first day of treatment. A typical study design is shown in Table 1 below. Typical dosage concentrations are set forth in Table 1, however the skilled artisan will readily understand that such concentrations may be modified. [0238]
    TABLE 1
    Assay Parameters
    Appli-
    Concen- cation Length
    Group # Animal # Compound tration volume of Study
    1  1-10 Test 0.01% in 400 μL 26 days
    Compound vehicle** topical
    2 11-20 Positive 0.01% in 400 μL 26 days
    Control vehicle** topical
    (T3)*
    3 21-30 Vehicle** N/A 400 μL 26 days
    topical
  • The mice are treated topically Monday through Friday on their lower back (base of tail to the lower rib). A pipettor and tip are used to deliver 400 A to each mouse's back. The 400 μL application is applied slowly while moving hair on the mouse to allow the application to reach the skin. [0239]
  • While each treatment is being applied to the mouse topically, a visual grade of from 0 to 4 will be given to the skin color in the application area of each animal. As a mouse converts from telogen to anagen, its skin color will become more bluish-black. As indicated in Table 2, the grades 0 to 4 represent the following visual observations as the skin progresses from white to bluish-black. [0240]
    TABLE 2
    Evaluation Criteria
    Visual Observation Grade
    Whitish Skin Color 0
    Skin is light gray (indication of initiation of anagen) 1
    Appearance of Blue Spots 2
    Blue Spots are aggregating to form one large blue area 3
    Skin is dark blue (almost black) with color covering majority of 4
    treatment area (indication of mouse in full anagen)
  • Example 1
  • [0241]
    Figure US20020037914A1-20020328-C00004
  • was tested according to the method of Reference Example 1. The average grade was calculated by averaging the grades of 7 mice after 23 days, 25 days, and 26 days. The results are in Table 3. The PGF grew hair. [0242]
  • Example 2
  • [0243]
    Figure US20020037914A1-20020328-C00005
  • was tested according to the method of Reference Example 1. The average grade was calculated by averaging the grades of 7 mice after 23 days. The results are in Table 3. The PGF grew hair. [0244]
    TABLE 3
    Average Grades
    Example 23 Days 25 Days 26 Days
    1 0.4 0.1 0.7
    2 0.1 not measured not measured
  • Example 3
  • Compositions for topical administration are made, comprising: [0245]
    Component 3-1 3-2 3-3
    PGF (wt %) 0.07 0.1 2.4
    IC50 the PGF (nM) 7 10 24
    Ethanol (wt %) 59.958 59.9 58.6
    Propylene Glycol (wt %) 19.986 20.0 19.5
    Dimethyl Isosorbide (wt %) 19.986 20.0 19.5
  • The PGFs in the compositions are as follows: [0246]
    Sample PGF
    3-1
    Figure US20020037914A1-20020328-C00006
    3-2
    Figure US20020037914A1-20020328-C00007
    3-3
    Figure US20020037914A1-20020328-C00008
  • A human male subject suffering from male pattern baldness is treated by a method of this invention. Specifically, for 6 weeks, one of the above compositions is daily administered topically to the subject to induce hair growth. [0247]
  • Example 4
  • A composition for topical administration is made according to the method of Dowton et al., “Influence of Liposomal Composition on Topical Delivery of Encapsulated Cyclosporin A: I. An in vitro Study Using Hairless Mouse Skin”, [0248] S.T.P. Pharma Sciences, Vol. 3, pp. 404-407 (1993), using a PGF in lieu of cyclosporin A and using the NOVASOME® 1 (available from Micro-Pak, Inc. of Wilmington, Del.) for the non-ionic liposomal formulation.
  • A human male subject suffering from male pattern baldness is treated each day with the above composition. Specifically, for 6 weeks, the above composition is administered topically to the subject. [0249]
  • Example 5
  • Shampoos are made, comprising: [0250]
    Component Ex. 5-1 Ex. 5-2 Ex. 5-3 Ex. 5-4
    Ammonium Lauryl Sulfate 11.5% 11.5% 9.5% 7.5%
    Ammonium Laureth Sulfate 4% 3% 2% 2%
    Cocamide MEA 2% 2% 2% 2%
    Ethylene Glycol Distearate 2% 2% 2% 2%
    Cetyl Alcohol 2% 2% 2% 2%
    Stearyl Alcohol 1.2% 1.2% 1.2% 1.2%
    Glycerin 1% 1% 1% 1%
    Polyquaternium 10 0.5% 0.25%
    Polyquaternium 24 0.5% 0.25%
    Sodium Chloride 0.1% 0.1% 0.1% 0.1%
    Sucrose Polyesters of Cottonate 3% 3%
    Fatty Acid
    Sucrose Polyesters of Behenate 2% 3%
    Fatty Acid
    Polydimethyl Siloxane 3% 2%
    Cocaminopropyl Betaine 1% 3% 3%
    Lauryl Dimethyl Amine Oxide 1.5% 1.5% 1.5% 1.5%
    Decyl Polyglucose 1% 1%
    DMDM Hydantoin 0.15% 0.15% 0.15% 0.15%
    PGF having IC50 of 7 nM 0.007% 0.007%
    PGF having IC50 of 24 nM 0.024% 0.024%
    Minoxidil 3% 2%
    Phenoxyethanol 0.5% 0.5% 0.5% 0.5%
    Fragrance 0.5% 0.5% 0.5% 0.5%
    Water q.s. q.s. q.s. q.s.
  • A human subject suffering from male pattern baldness is treated by a method of this invention. Specifically, for 12 weeks, a shampoo described above is used daily by the subject. [0251]
  • Example 6
  • A mascara composition is prepared. The composition comprises: [0252]
    Component % W/W
    WATER, DEIONIZED, USP q.s.
    BLACK 1080 MICRONIZED TYPE 10.000
    GLYCERYL MONOSTEARATE (2400 TYPE) 8.500
    C18-36 ACID TRIGLYCERIDE 5.500
    STEARIC ACID, TRIPLE PRESSED, LIQUID 4.000
    ETHYL ALCOHOL SD 40-B, 190 PROOF/SERIAL #: 4.000
    BEESWAX WHITE, FLAKES 3.250
    SHELLAC, NF 3.000
    LECITHIN, GRANULAR (TYPE 6450) 2.500
    TRIETHANOLAMINE 99% - TANK 2.470
    PARAFFIN WAX 2.250
    PARAFFIN WAX 118/125 2.250
    CARNAUBA WAX, NF 2.000
    POTASSIUM CETYL PHOSPHATE 1.000
    PHENOXYETHANOL 0.800
    OLEIC ACID NF 0.750
    DL-PANTHENOL 0.350
    PVPIVA COPOLYMER 0.250
    METHYLPARABEN, NF 0.200
    DIAZOLIDINYL UREA 0.200
    SIMETHICONE 0.200
    ETHYLPARABEN NF 0.150
    PENTAERYTHRITYL HYDROGENATED ROSINATE 0.150
    PROPYLPARABEN. NF 0.100
    TRISODIUM EDTA 0.100
    PGF having IC50 of 7 nM 0.007
  • The PGF is the same as that in Example 3-1. [0253]
  • A human female subject applies the composition each day. Specifically, for 6 weeks, the above composition is administered topically to the subject to darken and thicken eyelashes. [0254]
  • Example 7
  • Pharmaceutical compositions in the form of tablets are prepared by conventional methods, such as mixing and direct compaction, formulated as follows: [0255]
    Ingredient Quantity (mg per tablet)
    PGF 0.5
    Microcrystalline Cellulose 100
    Sodium Starch Glycollate 30
    Magnesium Stearate 3
  • The prostaglandin is the same as that in Example 3-3. [0256]
  • The above composition is administered orally to a subject once daily for 6 to 12 weeks to promote hair growth. [0257]
  • Example 8
  • Pharmaceutical compositions in liquid form are prepared by conventional methods, formulated as follows: [0258]
    Ingredient Quantity
    PGF 0.1 mg
    Phosphate buffered physiological saline 10 ml
    Methyl Paraben 0.05 ml
  • The prostaglandin is the same as that in Example [0259] 3-3.
  • 1.0 ml of the above composition is administered subcutaneously at the site of hair loss once daily for 6 to 12 weeks to promote hair growth. [0260]
  • Example 9
  • A topical pharmaceutical composition is prepared by conventional methods and formulated as follows: [0261]
    Ingredient Amount (wt %)
    PGF 0.004
    Dextran 70 0.1
    Hydroxypropyl methylcellulose 0.3
    Sodium Chloride 0.77
    Potassium chloride 0.12
    Disodium EDTA (Edetate disodium) 0.05
    Benzalkonium chloride 0.01
    HCL and/or NaOH pH 7.2-7.5
    Purified water q.s. to 100%
  • The prostaglandin is the same as that in Example 3-3. [0262]
  • The above composition is administered ocularly to a subject once per day for 6 to 12 weeks to promote eyelash growth. [0263]
  • Effects of the Invention
  • The compositions and methods herein provide a cosmetic benefit with respect to hair growth and appearance in subjects desiring such treatment.[0264]

Claims (44)

    What is claimed is:
  1. 1. A topical composition for treating hair loss comprising:
    A) an active ingredient selected from the group consisting of a prostaglandin F analog having the structure
    Figure US20020037914A1-20020328-C00009
    and pharmaceutically acceptable salts and hydrates of the prostaglandin F analog; biohydrolyzable amides, esters, and imides of the prostaglandin F analog; optical isomers, diastereomers, and enantiomers of the prostaglandin F analog; and combinations thereof;
    wherein R1 is selected from the group consisting of CO2H, C(O)NHOH, CO2R5, CH2OH, S(O)2R5, C(O)NHR5, C(O)NHS(O)2R5, and tetrazole;
    R2 is selected from the group consisting of a hydrogen atom and a lower monovalent hydrocarbon group;
    R3 and R4 are each independently selected from the group consisting of H, CH3, C2H5, OR10, SR10, and OH; with the proviso that both R3 and R4 are not OH;
    R5 is selected from the group consisting of monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, aromatic groups, substituted aromatic groups, carbocyclic groups, substituted carbocyclic groups, heterogeneous groups, substituted heterogeneous groups, heterocyclic groups, substituted heterocyclic groups, heteroaromatic groups, and substituted heteroaromatic groups;
    X is selected from the group consisting of NR6R7, OR8, SR9, S(O)R9, and S(O)2R9;
    R6, R7, and R8 are each independently selected from the group consisting of hydrogen atoms, acyl groups, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, carbocyclic groups, substituted carbocyclic groups, aromatic groups, substituted aromatic groups, heteroaromatic groups, and substituted heteroaromatic groups;
    R9 is selected from the group consisting of monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, carbocyclic groups, substituted carbocyclic groups, heterocyclic groups, substituted heterocyclic groups, aromatic groups, substituted aromatic groups, heteroaromatic groups, and substituted heteroaromatic groups;
    R10 is selected from the group consisting of a monovalent hydrocarbon group, a substituted monovalent hydrocarbon group, a heterogeneous group, a substituted heterogeneous group, a carbocyclic group, a substituted carbocyclic group, an aromatic group, a substituted aromatic group, a heteroaromatic group, and a substituted heteroaromatic group; with the proviso that R10 has 1 to 8 member atoms;
    Y is selected from the group consisting of an oxygen atom, a divalent hydrocarbon group, a sulfur-containing moiety, and a nitrogen-containing group; and
    Z is selected from the group consisting of a carbocyclic group, a substituted carbocyclic group, a heterocyclic group, a substituted heterocyclic group, an aromatic group, a substituted aromatic group, a heteroaromatic group, and a substituted heteroaromatic group; and
    B) a carrier.
  2. 2. The composition of claim 1, wherein R1 is selected from the group consisting of CO2H, CO2CH3, CO2C2H5, CO2C3H7, CO2C4H9, CO2C3H7O2, and C(O)NHS(O)2R5.
  3. 3. The composition of claim 1, wherein R5 is selected from the group consisting of CH3, C2H5, and C3H7.
  4. 4. The composition of claim 1, wherein R2 is selected from the group consisting of a hydrogen atom and a methyl group.
  5. 5. The composition of claim 1, wherein R3 and R4 are both hydrogen atoms.
  6. 6. The composition of claim 1, wherein X is selected from the group consisting of NR6R7 and OR8.
  7. 7. The composition of claim 1, wherein R6 and R7 are each independently selected from the group consisting of H, CH3, and C2H5.
  8. 8. The composition of claim 1, wherein R8 is selected from the group consisting of H, CH3, C2H5, and C3H7.
  9. 9. The composition of claim 1, wherein R9 is selected from the group consisting of CH3, and C2H5.
  10. 10. The composition of claim 1, wherein Y is a divalent hydrocarbon group having the formula (CH2)n, wherein n is 1.
  11. 11. The composition of claim 1, wherein Y is selected from the group consisting of a sulfur atom, an oxygen atom, S(O), and S(O)2.
  12. 12. The composition of claim 1, wherein Y is a nitrogen-containing group having the formula NR11; wherein R11 is selected from the group consisting of a hydrogen atom, an acyl group, a monovalent hydrocarbon group, a substituted monovalent hydrocarbon group, a heterogeneous group, a substituted heterogeneous group, a carbocyclic group, a substituted carbocyclic group, a heterocyclic group, a substituted heterocyclic group, an aromatic group, a substituted aromatic group, a heteroaromatic group, and a substituted heteroaromatic group.
  13. 13. The composition of claim 1, wherein Z is selected from the group consisting of a monocyclic carbocyclic group, a substituted monocyclic carbocyclic group, a monocyclic heterocyclic group, a substituted monocyclic heterocyclic group, a monocyclic aromatic group, a substituted monocyclic aromatic group, a monocyclic heteroaromatic group, and a substituted monocyclic heteroaromatic group.
  14. 14. The composition of claim 1, wherein component A) is added in an amount of
    IC 50×10−2≧% of component A)≧IC 50×10−3,
    where IC50 of component A) is expressed in nanomolar units.
  15. 15. The composition of claim 1, wherein component C) is added to the composition in an amount of 1 to 20%, and a sufficient amount of component B) is added such that the amounts of components A), B), and C) combined equal 100%.
  16. 16. The composition of claim 1, wherein component B) comprises an ingredient selected from the group consisting of water, alcohols, aloe vera gel, allantoin, glycerin, vitamin A and E oils, mineral oil, propylene glycol, dimethyl isosorbide, polypropylene glycol-2 myristyl propionate, q) emollients, r) propellants, s) solvents, t) humectants, u) thickeners, v) powders, w) fragrances, and combinations thereof.
  17. 17. The composition of claim 16, wherein ingredient q) is selected from the group consisting of stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petrolatum, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, myristyl myristate, and combinations thereof.
  18. 18. The composition of claim 16, wherein ingredient r) is selected from the group consisting of propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide, and combinations thereof.
  19. 19. The composition of claim 16, wherein ingredient s) is selected from the group consisting of water, ethyl alcohol, methylene chloride, isopropanol, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulfoxide, dimethyl formamide, tetrahydrofuran, and combinations thereof.
  20. 20. The composition of claim 16, wherein ingredient t) is selected from the group consisting of glycerin, sorbitol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, gelatin, and combinations thereof.
  21. 21. The composition of claim 16, wherein ingredient v) is selected from the group consisting of chalk, talc, fullers earth, kaolin, starch, gums, colloidal silicon dioxide, sodium polyacrylate, tetra alkyl ammonium smectites, trialkyl aryl ammonium smectites, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate, and combinations thereof.
  22. 22. A method of treating hair loss comprising administering to a mammal a composition comprising:
    A) an active ingredient selected from the group consisting of a prostaglandin F analog having the structure
    Figure US20020037914A1-20020328-C00010
    and pharmaceutically acceptable salts and hydrates of the prostaglandin F analog; biohydrolyzable amides, esters, and imides of the prostaglandin F analog; optical isomers, diastereomers, and enantiomers of the prostaglandin F analog; and combinations thereof;
    wherein R1 is selected from the group consisting of CO2H, C(O)NHOH, CO2R5, CH2OH, S(O)2R5, C(O)NHR5, C(O)NHS(O)2R5, and tetrazole;
    R2 is selected from the group consisting of a hydrogen atom and a lower monovalent hydrocarbon group;
    R3 and R4 are each independently selected from the group consisting of H, CH3, C2H5, OR10, SR10, and OH; with the proviso that both R3 and R4 are not OH;
    R5 is selected from the group consisting of monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, aromatic groups, substituted aromatic groups, carbocyclic groups, substituted carbocyclic groups, heterogeneous groups, substituted heterogeneous groups, heterocyclic groups, substituted heterocyclic groups, heteroaromatic groups, and substituted heteroaromatic groups;
    X is selected from the group consisting of NR6R7, OR8, SR9, S(O)R9, and S(O)2R9;
    R6, R7, and R8 are each independently selected from the group consisting of hydrogen atoms, acyl groups, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, carbocyclic groups, substituted carbocyclic groups, aromatic groups, substituted aromatic groups, heteroaromatic groups, and substituted heteroaromatic groups;
    R9 is selected from the group consisting of monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, carbocyclic groups, substituted carbocyclic groups, heterocyclic groups, substituted heterocyclic groups, aromatic groups, substituted aromatic groups, heteroaromatic groups, and substituted heteroaromatic groups;
    R10 is selected from the group consisting of a monovalent hydrocarbon group, a substituted monovalent hydrocarbon group, a heterogeneous group, a substituted heterogeneous group, a carbocyclic group, a substituted carbocyclic group, an aromatic group, a substituted aromatic group, a heteroaromatic group, and a substituted heteroaromatic group; with the proviso that R10 has 1 to 8 member atoms;
    Y is selected from the group consisting of an oxygen atom, a divalent hydrocarbon group, a sulfur-containing moiety, and a nitrogen-containing group; and
    Z is selected from the group consisting of a carbocyclic group, a substituted carbocyclic group, a heterocyclic group, a substituted heterocyclic group, an aromatic group, a substituted aromatic group, a heteroaromatic group, and a substituted heteroaromatic group.
  23. 23. The method of claim 22, wherein R1 is selected from the group consisting of CO2H, CO2CH3, CO2C2H5, CO2C3H7, CO2C4H9, CO2C3H7O2, and C(O)NHS(O)2R5.
  24. 24. The method of claim 22, wherein R5 is selected from the group consisting of CH3, C2H5, and C3H7.
  25. 25. The method of claim 22, wherein R2 is selected from the group consisting of a hydrogen atom and a methyl group.
  26. 26. The method of claim 22, wherein R3 and R4 are both hydrogen atoms.
  27. 27. The method of claim 22, wherein X is selected from the group consisting of NR6R7 and OR.
  28. 28. The method of claim 22, wherein R6 and R7 are each independently selected from the group consisting of H, CH3, and C2H5.
  29. 29. The method of claim 22, wherein R8 is selected from the group consisting of H, CH3, C2H5, and C3H7.
  30. 30. The method of claim 22, wherein R9 is selected from the group consisting of CH3, and C2H5.
  31. 31. The method of claim 22, wherein Y is a divalent hydrocarbon group having the formula (CH2)n, wherein n is 1.
  32. 32. The method of claim 22, wherein Y is selected from the group consisting of a sulfur atom, an oxygen atom, S(O), and S(O)2.
  33. 33. The method of claim 22, wherein Y is a nitrogen-containing group having the formula NR11; wherein R11 is selected from the group consisting of a hydrogen atom, an acyl group, a monovalent hydrocarbon group, a substituted monovalent hydrocarbon group, a heterogeneous group, a substituted heterogeneous group, a carbocyclic group, a substituted carbocyclic group, a heterocyclic group, a substituted heterocyclic group, an aromatic group, a substituted aromatic group, a heteroaromatic group, and a substituted heteroaromatic group.
  34. 34. The method of claim 22, wherein Z is selected from the group consisting of a monocyclic carbocyclic group, a substituted monocyclic carbocyclic group, a monocyclic heterocyclic group, a substituted monocyclic heterocyclic group, a monocyclic aromatic group, a substituted monocyclic aromatic group, a monocyclic heteroaromatic group, and a substituted monocyclic heteroaromatic group.
  35. 35. The method of claim 22, wherein the composition is administered by a route selected from the group consisting of systemic and topical routes.
  36. 36. The method of claim 35, wherein the composition is a topical composition in a form selected from the group consisting of solutions, oils, creams, ointments, gels, lotions, shampoos, leave-on and rinse-out hair conditioners, milks, cleansers, moisturizers, sprays, and skin patches.
  37. 37. The method of claim 35, wherein the composition is a topical composition further comprising B) a carrier comprising an ingredient selected from the group consisting of water, alcohols, aloe vera gel, allantoin, glycerin, vitamin A and E oils, mineral oil, propylene glycol, dimethyl isosorbide, polypropylene glycol-2 myristyl propionate, q) emollients, r) propellants, s) solvents, t) humectants, u) I thickeners, v) powders, w) fragrances, and combinations thereof.
  38. 38. The method of claim 35, wherein the composition further comprises C) an activity enhancer selected from the group consisting of i) a hair growth stimulant, ii) a penetration enhancer, and combinations thereof.
  39. 39. The method of claim 38, wherein component i) is selected from the group vasodilator, an antiandrogen, a cyclosporin, a cyclosporin analog, an antimicrobial, an anti-inflammatory, a thyroid hormone, a thyroid hormone derivative, and a thyroid hormone analog, a non-selective prostaglandin agonist, a non-selective prostaglandin antagonist, a retinoid, a triterpene, and combinations thereof.
  40. 40. The method of claim 35, wherein component ii) is selected from the group consisting of 2-methyl propan-2-ol, propan-2-ol, ethyl-2-hydroxypropanoate, hexan-2,5-diol, polyoxyethylene(2) ethyl ether, di(2-hydroxypropyl) ether, pentan-2,4-diol, acetone, polyoxyethylene(2) methyl ether, 2-hydroxypropionic acid, 2-hydroxyoctanoic acid, propan-1-ol, 1,4-dioxane, tetrahydrofuran, butan-1,4-diol, propylene glycol dipelargonate, polyoxypropylene 15 stearyl ether, octyl alcohol, polyoxyethylene ester of oleyl alcohol, oleyl alcohol, lauryl alcohol, dioctyl adipate, dicapryl adipate, di-isopropyl adipate, di-isopropyl sebacate, dibutyl sebacate, diethyl sebacate, dimethyl sebacate, dioctyl sebacate, dibutyl suberate, dioctyl azelate, dibenzyl sebacate, dibutyl phthalate, dibutyl azelate, ethyl myristate, dimethyl azelate, butyl myristate, dibutyl succinate, didecyl phthalate, decyl oleate, ethyl caproate, ethyl salicylate, isopropyl palmitate, ethyl laurate, 2-ethyl-hexyl pelargonate, isopropyl isostearate, butyl laurate, benzyl benzoate, butyl benzoate, hexyl laurate, ethyl caprate, ethyl caprylate, butyl stearate, benzyl salicylate, 2-hydroxypropanoic acid, 2-hydroxyoctanoic acid, dimethyl sulphoxide, N,N-dimethyl acetamide, N,N-dimethyl formamide, 2-pyrrolidone, 1-methyl-2-pyrrolidone, 5-methyl-2-pyrrolidone, 1,5-dimethyl-2-pyrrolidone, 1-ethyl-2-pyrrolidone, phosphine oxides, sugar esters, tetrahydrofurfural alcohol, urea, diethyl-m-toluamide, 1-dodecylazacyloheptan-2-one, and combinations thereof.
  41. 41. The method of claim 35, wherein the composition is a topical composition locally administered on the skin once per day.
  42. 42. The method of claim 41, wherein the composition is administered once per day for 6 to 12 weeks.
  43. 43. A mascara composition comprising:
    A) an active ingredient selected from the group consisting of a prostaglandin F analog having the structure
    Figure US20020037914A1-20020328-C00011
    and pharmaceutically acceptable salts and hydrates of the prostaglandin F analog; biohydrolyzable amides, esters, and imides of the prostaglandin F analog; optical isomers, diastereomers, and enantiomers of the prostaglandin F analog; and combinations thereof;
    wherein R1 is selected from the group consisting of CO2H, C(O)NHOH, CO2R5, CH2OH, S(O)2R5, C(O)NHR5, C(O)NHS(O)2R5, and tetrazole;
    R2 is selected from the group consisting of a hydrogen atom and a lower monovalent hydrocarbon group;
    R3 and R4 are each independently selected from the group consisting of H, CH3, C2H5, OR10, SR10, and OH; with the proviso that both R3 and R4 are not OH;
    R is selected from the group consisting of monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, aromatic groups, substituted aromatic groups, carbocyclic groups, substituted carbocyclic groups, heterogeneous groups, substituted heterogeneous groups, heterocyclic groups, substituted heterocyclic groups, heteroaromatic groups, and substituted heteroaromatic groups;
    X is selected from the group consisting of NR6R6, OR8, SR8, S(O)R9, and S(O)2R9;
    R6, R7, and R8 are each independently selected from the group consisting of hydrogen atoms, acyl groups, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, carbocyclic groups, substituted carbocyclic groups, aromatic groups, substituted aromatic groups, heteroaromatic groups, and substituted heteroaromatic groups;
    R9 is selected from the group consisting of monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, carbocyclic groups, substituted carbocyclic groups, heterocyclic groups, substituted heterocyclic groups, aromatic groups, substituted aromatic groups, heteroaromatic groups, and substituted heteroaromatic groups;
    R10 is selected from the group consisting of a monovalent hydrocarbon group, a substituted monovalent hydrocarbon group, a heterogeneous group, a substituted heterogeneous group, a carbocyclic group, a substituted carbocyclic group, an aromatic group, a substituted aromatic group, a heteroaromatic group, and a substituted heteroaromatic group; with the proviso that R10 has 1 to 8 member atoms;
    Y is selected from the group consisting of an oxygen atom, a divalent hydrocarbon group, a sulfur-containing moiety, and a nitrogen-containing group; and
    Z is selected from the group consisting of a carbocyclic group, a substituted carbocyclic group, a heterocyclic group, a substituted heterocyclic group, an aromatic group, a substituted aromatic group, a heteroaromatic group, and a substituted heteroaromatic group,
    dd) a water-insoluble material,
    ee) a water-soluble, film-forming polymer,
    ff) a wax;
    o) a surfactant;
    gg) pigment; and
    s) a solvent.
  44. 44. A method for darkening and thickening hair comprising applying to growing hair and skin a composition comprising:
    A) an active ingredient selected from the group consisting of a prostaglandin F analog having the structure
    Figure US20020037914A1-20020328-C00012
     and pharmaceutically acceptable salts and hydrates of the prostaglandin F analog; biohydrolyzable amides, esters, and imides of the prostaglandin F analog; optical isomers, diastereomers, and enantiomers of the prostaglandin F analog; and combinations thereof;
    wherein R1 is selected from the group consisting Of CO2H, C(O)NHOH, CO2R1, CH2OH, S(O)2R5, C(O)NHR5, C(O)NHS(O)2R5, and tetrazole;
    R2 is selected from the group consisting of a hydrogen atom and a lower monovalent hydrocarbon group;
    R3and R4are each independently selected from the group consisting of H, CH3, C2H5, OR10, SR10, and OH; with the proviso that both R3 and R4 are not OH;
    R5 is selected from the group consisting of monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, aromatic groups, substituted aromatic groups, carbocyclic groups, substituted carbocyclic groups, heterogeneous groups, substituted heterogeneous groups, heterocyclic groups, substituted heterocyclic groups, heteroaromatic groups, and substituted heteroaromatic groups;
    X is selected from the group consisting of NR6R7, OR8, SR9, S(O)R9, and S(O)2R9;
    R6, R7, and R8 are each independently selected from the group consisting of hydrogen atoms, acyl groups, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, carbocyclic groups, substituted carbocyclic groups, aromatic groups, substituted aromatic groups, heteroaromatic groups, and substituted heteroaromatic groups;
    R9 is selected from the group consisting of monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, carbocyclic groups, substituted carbocyclic groups, heterocyclic groups, substituted heterocyclic groups, aromatic groups, substituted aromatic groups, heteroaromatic groups, and substituted heteroaromatic groups;
    R10 is selected from the group consisting of a monovalent hydrocarbon group, a substituted monovalent hydrocarbon group, a heterogeneous group, a substituted heterogeneous group, a carbocyclic group, a substituted carbocyclic group, an aromatic group, a substituted aromatic group, a heteroaromatic group, and a substituted heteroaromatic group; with the proviso that R10 has 1 to 8 member atoms;
    Y is selected from the group consisting of an oxygen atom, a divalent hydrocarbon group, a sulfur-containing moiety, and a nitrogen-containing group; and
    Z is selected from the group consisting of a carbocyclic group, a substituted carbocyclic group, a heterocyclic group, a substituted heterocyclic group, an aromatic group, a substituted aromatic group, a heteroaromatic group, and a substituted heteroaromatic group; and
    B) a carrier.
US09774555 2000-03-31 2001-01-31 Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins Abandoned US20020037914A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US19384600 true 2000-03-31 2000-03-31
US09774555 US20020037914A1 (en) 2000-03-31 2001-01-31 Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09774555 US20020037914A1 (en) 2000-03-31 2001-01-31 Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US11565297 US7407987B2 (en) 2000-03-31 2006-11-30 Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US12138733 US8618086B2 (en) 2000-03-31 2008-06-13 Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11565297 Division US7407987B2 (en) 2000-03-31 2006-11-30 Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins

Publications (1)

Publication Number Publication Date
US20020037914A1 true true US20020037914A1 (en) 2002-03-28

Family

ID=22715257

Family Applications (3)

Application Number Title Priority Date Filing Date
US09774555 Abandoned US20020037914A1 (en) 2000-03-31 2001-01-31 Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US11565297 Active US7407987B2 (en) 2000-03-31 2006-11-30 Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US12138733 Active 2021-03-12 US8618086B2 (en) 2000-03-31 2008-06-13 Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11565297 Active US7407987B2 (en) 2000-03-31 2006-11-30 Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US12138733 Active 2021-03-12 US8618086B2 (en) 2000-03-31 2008-06-13 Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins

Country Status (8)

Country Link
US (3) US20020037914A1 (en)
EP (1) EP1267803B1 (en)
JP (2) JP2003528897A (en)
CN (1) CN1206976C (en)
CA (1) CA2401718C (en)
DE (2) DE60115869T2 (en)
ES (1) ES2254395T3 (en)
WO (1) WO2001074313A3 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183399A1 (en) * 2001-05-09 2002-12-05 Sewon Kang Method and compositions for treating rosacea
US20060121069A1 (en) * 2000-03-31 2006-06-08 Duke University Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20060135609A1 (en) * 2004-10-21 2006-06-22 Duke University Ophthamological drugs
US20060247214A1 (en) * 2000-03-31 2006-11-02 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US20080033036A1 (en) * 2003-08-12 2008-02-07 Ryuji Ueno Composition and Method for Promoting Hair Growth
US20090286769A1 (en) * 2000-03-31 2009-11-19 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20100105775A1 (en) * 2008-10-29 2010-04-29 Delong Mitchell A Amino acid salts of prostaglandins
US20100221197A1 (en) * 2007-11-27 2010-09-02 Taiyo Corporation Antimicrobial agent and external preparation for skin containing the same
USRE43372E1 (en) 1999-03-05 2012-05-08 Duke University C16 unsaturated FP-selective prostaglandins analogs
US8618086B2 (en) 2000-03-31 2013-12-31 Duke University Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US9006291B2 (en) 2009-02-03 2015-04-14 Pharma Patent Holding Inc. Composition, method and kit for enhancing hair

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
FR2920309B1 (en) 2007-08-28 2010-05-28 Galderma Res & Dev Using travoprost to treat hair loss
US8455547B2 (en) * 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
US7964596B2 (en) * 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
WO2010064203A1 (en) 2008-12-02 2010-06-10 L'oreal Combination of reduced glutathione and amino acids for improving the quality of the hair in women
WO2011014649A1 (en) 2009-07-29 2011-02-03 Duke University Compositions and methods for inhibiting hair growth
FR2949052B1 (en) 2009-08-13 2015-03-27 Oreal Process for cosmetic treatment of the scalp.
CA2780267A1 (en) 2009-11-09 2011-05-12 Allergan, Inc. Compositions and methods for stimulating hair growth
EP3295940A1 (en) 2012-04-16 2018-03-21 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
US20150190383A1 (en) * 2014-01-08 2015-07-09 Aida Kalley Hair care composition with analgesic
JP2015186776A (en) * 2014-03-26 2015-10-29 三菱化学株式会社 Zeolite membrane evaluation method

Citations (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3435053A (en) * 1966-06-06 1969-03-25 Upjohn Co Cyclopenta(b)pyrans
US3524867A (en) * 1966-06-06 1970-08-18 Upjohn Co Process for producing cyclopenta (b)pyrans
US3598858A (en) * 1958-05-28 1971-08-10 Sune Bergstrom Pge2 and pge3
US3776939A (en) * 1958-05-28 1973-12-04 S Bergstrom Dihydro-pgf1a
US3776938A (en) * 1958-05-28 1973-12-04 S Bergstrom Dihydro-pge1
US3839409A (en) * 1958-05-28 1974-10-01 Kemiska Inst Karolinska I Pge3 esters and alkanoates
US3882241A (en) * 1969-12-01 1975-05-06 Upjohn Co Use of prostaglandins E and F for prevention of pregnancy in humans
US3882245A (en) * 1972-11-01 1975-05-06 Upjohn Co Use of prostaglandins in combating shock
US3896156A (en) * 1970-06-30 1975-07-22 Upjohn Co Dihydroprostaglandin e, analogs
US3928588A (en) * 1974-02-22 1975-12-23 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US3966792A (en) * 1973-02-28 1976-06-29 Ono Pharmaceutical Co., Ltd. Prostaglandin compounds
US3984455A (en) * 1973-07-16 1976-10-05 The Upjohn Company Prostaglandin E1 analogs
US4004020A (en) * 1973-12-21 1977-01-18 Schering Aktiengesellschaft Novel prostanoic acid derivatives and process for the preparation thereof
US4011262A (en) * 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
US4024179A (en) * 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
US4061671A (en) * 1974-04-03 1977-12-06 Hoechst Aktiengesellschaft Analogues of prostaglandins
US4073934A (en) * 1975-04-18 1978-02-14 Schering Aktiengesellschaft Novel acetylenic prostaglandin analogs
US4089885A (en) * 1976-11-05 1978-05-16 American Home Products Corporation Prostaglandin derivatives
US4123441A (en) * 1976-09-22 1978-10-31 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
US4128720A (en) * 1975-02-14 1978-12-05 Ono Pharmaceutical Company Prostaglandin analogues
US4158667A (en) * 1976-02-04 1979-06-19 The Upjohn Company 6-Keto PGF analogs
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4217360A (en) * 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
US4225508A (en) * 1979-07-05 1980-09-30 The Upjohn Company 19-Hydroxy-PGI2 compounds
US4225507A (en) * 1979-07-05 1980-09-30 The Upjohn Company 19-Hydroxy-19-methyl-PGI2 compounds
US4284646A (en) * 1976-08-06 1981-08-18 Schering Aktiengesellschaft Prostanoic acid derivatives and their preparation
US4499293A (en) * 1976-09-22 1985-02-12 The Upjohn Company PGI2 Salts
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4704386A (en) * 1985-08-29 1987-11-03 G. D. Searle & Co. 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides
US4889845A (en) * 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
US5063057A (en) * 1990-09-26 1991-11-05 Elizabeth Arden Co., Division Of Conopco, Inc. Cosmetic capsules
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US5340813A (en) * 1992-11-09 1994-08-23 Cell Therapeutics, Inc. Substituted aminoalkyl xanthine compounds
US5422371A (en) * 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5508303A (en) * 1992-05-29 1996-04-16 Toray Industries, Inc. Hair-growing composition
US5516652A (en) * 1993-10-06 1996-05-14 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor IP
US5567079A (en) * 1992-11-17 1996-10-22 Felder; Anton Method for the hydraulic branching of an open stream and hydraulically working channel branch
US5576315A (en) * 1991-05-03 1996-11-19 G.D. Searle & Co. Substituted dibenzoxazepine compounds and methods for treating osteoporosis and ischemia
US5578643A (en) * 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5587391A (en) * 1993-12-28 1996-12-24 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US5641494A (en) * 1992-03-20 1997-06-24 Janssen Pharmaceutica N.V. Agent for regulating the greasiness of the skin
US5658897A (en) * 1996-04-08 1997-08-19 Allergan Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents
US5663203A (en) * 1986-09-11 1997-09-02 Schering Aktiengesellschaft Agents containing prostacyclin derivatives for topical application
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
US5716609A (en) * 1995-07-25 1998-02-10 Panacea Biotec Limited Therapeutic anti-inflammatory and analgesic composition containing nimesulide for use transdermally and a process for the manufacture thereof
US5719140A (en) * 1993-04-30 1998-02-17 G.D. Searle & Co. 2, 3-, 4-, 5-, 6-, 7-, 8-, 9- and /or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5770759A (en) * 1987-04-30 1998-06-23 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5792851A (en) * 1996-09-03 1998-08-11 Albert Einstin College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Human prostaglandin transporter
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5840847A (en) * 1993-06-25 1998-11-24 Merck Frosst Canada, Inc. Purified prostaglandin receptor FP
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
US5885766A (en) * 1995-02-17 1999-03-23 Societe L'oreal S.A. Method of screening of substances for their effect on the expression of mediators of inflammation in a hair follicle
US5885974A (en) * 1994-12-06 1999-03-23 Michael M. Danielov Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
US5889052A (en) * 1993-08-03 1999-03-30 Alcon Laboraties, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5892099A (en) * 1997-01-27 1999-04-06 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
US5958723A (en) * 1995-01-26 1999-09-28 Merck Frosst Canada & Co. DNA encoding prostaglandin receptor DP
US5972965A (en) * 1995-07-21 1999-10-26 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryl oxazole derivatives
US5977173A (en) * 1997-09-09 1999-11-02 Wos; John August Aromatic C16 -C20 -substituted tetrahydro prostaglandins useful as FP agonists
US5985597A (en) * 1993-05-26 1999-11-16 Merck Frosst Canada, Inc. DNA encoding prostaglandin receptor EP1
US5990346A (en) * 1995-06-26 1999-11-23 Teijin Limited Prostaglandins and processes for production thereof
US5994397A (en) * 1995-12-22 1999-11-30 Alcon Laboratories, Inc. Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US6013823A (en) * 1992-06-08 2000-01-11 New Pharma International Corp. Trans-pentavalent 2-15-deoxy-16-hydroxy-16-methyl-PGE1 methyl ester (B-407)
US6025375A (en) * 1993-12-20 2000-02-15 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole derivatives
US6030959A (en) * 1997-04-04 2000-02-29 Monsanto Company Gastro-specific prodrugs
US6031001A (en) * 1994-09-21 2000-02-29 Synphra Ab Use of prostaglandins
US6030999A (en) * 1988-09-06 2000-02-29 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6037364A (en) * 1992-09-21 2000-03-14 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6037368A (en) * 1997-05-09 2000-03-14 Mount Sinai School Of Medicine 8-iso- prostaglandins for glaucoma therapy
US6043264A (en) * 1995-01-06 2000-03-28 Toray Industries, Inc. Benzene-condensed heterocyclic derivatives and their uses
US6048895A (en) * 1997-09-09 2000-04-11 The Procter & Gamble Company Aromatic C16-C20 substituted tetrahydro prostaglandins useful as FP agonists
US6110969A (en) * 1997-02-04 2000-08-29 Ono Pharmaceutical Co. Ltd. Cycloalkyl-prostaglandin E2 derivatives
US6262105B1 (en) * 1997-02-04 2001-07-17 Murray A. Johnstone Method of enhancing hair growth

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US13294A (en) 1855-07-17 Improved apparatus for cooling repeating fire-arms
US37914A (en) 1863-03-17 Improved automatic nose-bag
US37913A (en) 1863-03-17 Improvement in sewing-machines
US146439A (en) 1874-01-13 Improvement in pruning-shears
DE1617477U (en) 1950-09-27 1950-12-14 Heinrich Dressel Wheel holder for raeder, such as for strollers and small vehicles.
US3382247A (en) 1965-11-01 1968-05-07 Upjohn Co 6-amino-1, 2-dihydro-1-hydroxy-2-imino-4-phenoxypyrimidines
US3538120A (en) 1967-05-22 1970-11-03 Ciba Geigy Corp Cyclopentyl-alkanoic acids
US3636120A (en) 1967-10-09 1972-01-18 Upjohn Co Prostaglandin e primary alcohols
GB1285372A (en) 1968-08-29 1972-08-16 Upjohn Co Improvements in or relating to prostaglandins and the preparation thereof
GB1251750A (en) 1968-11-12 1971-10-27
BE755555A (en) 1969-09-02 1971-03-01 Richardson Merrell Inc Quinoxaline derivatives
FR2108027B1 (en) 1970-09-28 1974-03-29 Curt Georgi Imes Spa
BE791369A (en) 1971-11-16 1973-05-14 American Cyanamid Co Cyanurates tris (meta-hydroxybenzyl) subject to a steric impediment and useful as antioxidants
US3798275A (en) 1972-04-05 1974-03-19 Ciba Geigy Corp Etherified mercapto-methoxyamines
US4304907A (en) 1972-05-10 1981-12-08 The Upjohn Company Bicyclo lactone intermediates for prostaglandin analogs
US3974213A (en) 1972-07-13 1976-08-10 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins
NL7315307A (en) 1972-11-08 1974-05-10
US4152527A (en) 1972-11-08 1979-05-01 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
ES420325A1 (en) 1972-11-08 1976-04-16 Pfizer A process for preparing a prostaglandin.
US3984424A (en) 1972-11-08 1976-10-05 Pfizer Inc. P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins
FR2239458B3 (en) 1973-07-31 1976-07-16 Aries Robert
US3931282A (en) 1974-02-21 1976-01-06 Syntex (U.S.A.) Inc. 11α-Hydroxymethyl prostaglandins
US4069885A (en) * 1974-03-27 1978-01-24 Klockner-Humboldt-Deutz Aktiengesellschaft Tractor-implement arrangement for establishing frictional engagement therebetween
GB1458315A (en) 1974-04-22 1976-12-15 Ici Ltd Prostanoic acid derivatives
DE2460990A1 (en) 1974-12-21 1976-07-01 Hoechst Ag New prostaglandin analogs and methods for their production
US3934013A (en) 1975-02-21 1976-01-20 Syntex (U.S.A.) Inc. Pharmaceutical composition
GB1506816A (en) 1975-03-31 1978-04-12 Upjohn Co Prostaglandins
GB1520522A (en) 1975-06-16 1978-08-09 Ono Pharmaceutical Co 16-methyleneprostaglandins
ES449162A1 (en) 1975-06-23 1977-12-16 Syntex Inc A process for the preparation of a compound or racemi-co-antimerico 8r.
US4005133A (en) 1975-10-14 1977-01-25 The Upjohn Company PGF2.sub.α, L-Arginine salt
US4128577A (en) 1975-12-29 1978-12-05 The Upjohn Company 15-Methyl- and 16-phenoxy-PGF2 α, amides
US4596812A (en) 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
US4139619A (en) 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4051238A (en) 1976-06-03 1977-09-27 The Upjohn Company Treatment of genital tract diseases of domestic animals with prostaglandins
US4268522A (en) 1976-06-14 1981-05-19 Pfizer Inc. 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof
DE2737808A1 (en) 1976-08-27 1978-03-16 Pfizer 2-substituted heterocyclic aryl-omega-pentanorprostaglandine
DE2737807A1 (en) 1976-08-27 1978-03-09 Pfizer C. deeply 1 -p-biphenyl of omega-pentanorprostaglandinen
US4178457A (en) 1978-07-10 1979-12-11 Syntex (U.S.A.) Inc. (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof
US4206151A (en) 1978-12-21 1980-06-03 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl or cyclopropyl prostan-1-ols of the E, A and F series
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
GB2048254B (en) 1979-04-02 1983-05-25 Upjohn Co 19,20 -didehydro-19-hydroxy and 19-oxo-prostaglandin derivatives
US4296504A (en) 1980-07-07 1981-10-27 Lawson Daniel C Toilet seat lock
US4543353A (en) 1981-11-27 1985-09-24 Farmitalia Carlo Erba S.P.A. Ester and amide derivatives of 13,14-didehydro prostaglandins
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4912235A (en) 1983-12-22 1990-03-27 Syntex (U.S.A.) Inc. Processes and intermediates for making 16-phenoxy- and 16-substituted phenoxy-prostatrienoic acid derivatives and their stereoisomers
ES545700A0 (en) 1984-07-31 1986-06-16 Syntex Inc Process for preparing derivatives of acids 11-subbed-2-16-phenoxy and 16-substituted phenoxy-prostatrienoicos
JPH0341464B2 (en) 1984-11-21 1991-06-24
JPH0473406B2 (en) * 1985-03-22 1992-11-20 Kenichi Katsu
US4757089A (en) 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5863948A (en) 1985-06-14 1999-01-26 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
FI872552A (en) * 1986-06-09 1987-12-10 American Cyanamid Co Prostaglandinkomposition Foer lokalt bruk.
US5041439A (en) 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4883819A (en) 1986-07-31 1989-11-28 The Trustees Of Columbia University In The City Of New York Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
US4952581A (en) 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
GB8713747D0 (en) 1987-06-12 1987-07-15 Unilever Plc Skin treatment composition
US5166178B1 (en) 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
DE3876050T2 (en) 1987-09-18 1993-03-25 R Tech Ueno Ltd Ocular hypotensivagenzien.
US5321128A (en) 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5194429A (en) 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
US4968812A (en) 1989-06-23 1990-11-06 Shell Oil Company Spirolactonelactams
CA1339132C (en) 1989-09-12 1997-07-29 Johan W. Stjernschantz Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2039420C (en) 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
US5302617A (en) 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
US5312832A (en) 1991-05-17 1994-05-17 Allergan, Inc. Ocular hypotensive 2-decarboxyl-2-acylthioalkyl prostaglandin derivatives
US5288754A (en) 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
CA2146127C (en) 1992-10-13 2000-06-13 Louis Desantis, Jr. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
US5332730A (en) 1992-10-16 1994-07-26 Allergan, Inc. Azido derivatives of cyclopentane heptanoic or heptenoic acid
WO1995011003A1 (en) * 1993-10-20 1995-04-27 Pharmacia Ab New use of prostaglandins
WO1995012401A1 (en) 1993-11-03 1995-05-11 Pharmacia Ab Method and means for prevention of cataract
US5431881A (en) 1993-12-10 1995-07-11 Palacios; Henry J. Treatment of hair loss and dermatological problems
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5458883A (en) 1994-01-12 1995-10-17 Duke University Method of treating disorders of the eye
US5489470A (en) 1994-01-28 1996-02-06 The Procter & Gamble Company Biodegradable copolymers and plastic articles comprising biodegradable copolymers
US5476372A (en) 1994-02-10 1995-12-19 Yang; Hsi-Kung Manual pump
US6169111B1 (en) 1995-06-07 2001-01-02 Alcon Laboratories, Inc. Conformationally rigid aryl prostaglandins for use in glaucoma therapy
US5698733A (en) 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
FR2730811B1 (en) 1995-02-17 1997-03-21 Oreal A method for diagnosing and / or monitoring the evolution of a capillary disorder and / or measure the effectiveness of a treatment applied to combat a capillary disorder
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
JP3049593B2 (en) * 1996-05-01 2000-06-05 日本ソシア株式会社 Hair growth tonic
DK1008588T3 (en) 1997-02-10 2003-07-28 Ono Pharmaceutical Co 11,15-O-dialkyl prostaglandin E derivatives, to processes for their preparation and pharmaceutical compositions comprising them as an active ingredient
JP3217293B2 (en) * 1997-04-17 2001-10-09 株式会社アールテック・ウエノ Hair growth and hair tonic
WO1999012899A1 (en) * 1997-09-09 1999-03-18 The Procter & Gamble Company A process for making prostaglandin f analogs
CA2303763C (en) * 1997-09-09 2007-04-24 The Procter & Gamble Company Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
WO1999015502A1 (en) 1997-09-19 1999-04-01 Shionogi & Co., Ltd. Compounds having [2.2.1]bicyclo skeleton
WO1999032441A1 (en) 1997-12-22 1999-07-01 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
GB9802599D0 (en) 1998-02-07 1998-04-01 Glaxo Group Ltd Medical use
US6444840B1 (en) 1998-03-31 2002-09-03 The Procter & Gamble Co. C11 oxymyl and hydroxylamino prostaglandins useful as FP agonists
CA2324343C (en) 1998-03-31 2005-05-31 The Procter & Gamble Company C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6121253A (en) 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
EP1159265B1 (en) 1999-03-05 2004-11-24 Duke University C-16 unsaturated fp-selective prostaglandins analogs
DE60015508D1 (en) 1999-03-05 2004-12-09 Univ Durham C-16 ungesätigte fp-selective prostaglandin analog
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
EP1202999B1 (en) 1999-08-04 2003-06-18 THE PROCTER & GAMBLE COMPANY Novel 2-decarboxy-2-phosphinico prostaglandin f analogs
US6548535B2 (en) 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
CN1366458A (en) 2000-03-31 2002-08-28 东丽株式会社 Hair growth and hair formation controlling agents
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020146439A1 (en) 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
FR2812193B1 (en) 2000-07-28 2003-10-24 Oreal Using receptor antagonist ep-2 prostaglandins and / or EP-4 to alleviate, reduce or stop the growth of hair and hairs in cosmetic preparations
FR2812190B1 (en) 2000-07-28 2003-01-31 Oreal Use of non-prostanoic receptor agonists ep-2 prostaglandins and / or EP-4 as a cosmetic agent to mitigate, reduce or to stop hair loss and hair
FR2812191B1 (en) 2000-07-28 2003-10-17 Oreal Using receptor agonists of prostaglandin e2 (EP-3) to mitigate, reduce or stop hair growth and hair in cosmetic preparations
US20040082013A1 (en) 2002-01-24 2004-04-29 Regan John W Methods for screening for substances which inhibit fp prostanoid receptor interaction with a compound having pgf2alpha activity and methods of treating cancer
US7157590B2 (en) 2001-05-31 2007-01-02 Finetech Laboratories Ltd. Process for the preparation of 17-phenyl-18,19,20-thinor-pgf 2a and its derivatives
US20030199590A1 (en) 2002-07-25 2003-10-23 Cagle Gerald D Prostaglandin analogues for promotion of hair growth
EP1298223A3 (en) 2001-09-28 2003-07-23 Pfizer Products Inc. Methods related to the A-C repeat Z-sequence upstream from the aldose reductase gene
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US7186707B2 (en) 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
GB0208785D0 (en) 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
US7320967B2 (en) 2002-04-23 2008-01-22 L'oreal Cosmetic composition, method of cosmetic treatment and preparation of a composition for promoting the growth and/or preventing or delaying the loss of hair
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7045634B2 (en) 2003-09-05 2006-05-16 Allergan, Inc. Prostamide receptor antagonists
US20050058614A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
US7070768B2 (en) 2003-09-25 2006-07-04 Allergan, Inc. Method for imparting artificial tan to human skin
US20050112075A1 (en) 2003-11-25 2005-05-26 Hwang Cheng S. Reduction of hair growth
US8415364B2 (en) 2003-11-26 2013-04-09 Duke University Method of preventing or treating glaucoma
EP1812017A2 (en) 2004-10-21 2007-08-01 Duke University Ophthamological drugs
US7288029B1 (en) 2005-01-19 2007-10-30 Gkn Driveline North America, Inc. Propshaft with crash-worthiness
US20070254920A1 (en) 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US7868032B2 (en) 2006-10-18 2011-01-11 Allergan, Inc. Prostamide receptor antagonists
US20090018204A1 (en) 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins

Patent Citations (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776938A (en) * 1958-05-28 1973-12-04 S Bergstrom Dihydro-pge1
US3839409A (en) * 1958-05-28 1974-10-01 Kemiska Inst Karolinska I Pge3 esters and alkanoates
US3598858A (en) * 1958-05-28 1971-08-10 Sune Bergstrom Pge2 and pge3
US3691216A (en) * 1958-05-28 1972-09-12 Sune Bergstrom Pge2 methyl ester and pge2 methyl ester diacetate
US3706789A (en) * 1958-05-28 1972-12-19 Sune Bergstrom Pgf{11 {60
US3776939A (en) * 1958-05-28 1973-12-04 S Bergstrom Dihydro-pgf1a
US3852337A (en) * 1958-05-28 1974-12-03 Kemiska Institutionen Karolins Pgf tetraols and alkanoyl esters
US3435053A (en) * 1966-06-06 1969-03-25 Upjohn Co Cyclopenta(b)pyrans
US3524867A (en) * 1966-06-06 1970-08-18 Upjohn Co Process for producing cyclopenta (b)pyrans
US3882241A (en) * 1969-12-01 1975-05-06 Upjohn Co Use of prostaglandins E and F for prevention of pregnancy in humans
US3896156A (en) * 1970-06-30 1975-07-22 Upjohn Co Dihydroprostaglandin e, analogs
US4011262A (en) * 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
US3882245A (en) * 1972-11-01 1975-05-06 Upjohn Co Use of prostaglandins in combating shock
US4024179A (en) * 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
US3966792A (en) * 1973-02-28 1976-06-29 Ono Pharmaceutical Co., Ltd. Prostaglandin compounds
US3984455A (en) * 1973-07-16 1976-10-05 The Upjohn Company Prostaglandin E1 analogs
US4004020A (en) * 1973-12-21 1977-01-18 Schering Aktiengesellschaft Novel prostanoic acid derivatives and process for the preparation thereof
US3928588A (en) * 1974-02-22 1975-12-23 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US4061671A (en) * 1974-04-03 1977-12-06 Hoechst Aktiengesellschaft Analogues of prostaglandins
US4128720A (en) * 1975-02-14 1978-12-05 Ono Pharmaceutical Company Prostaglandin analogues
US4217360A (en) * 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
US4073934A (en) * 1975-04-18 1978-02-14 Schering Aktiengesellschaft Novel acetylenic prostaglandin analogs
US4158667A (en) * 1976-02-04 1979-06-19 The Upjohn Company 6-Keto PGF analogs
US4284646A (en) * 1976-08-06 1981-08-18 Schering Aktiengesellschaft Prostanoic acid derivatives and their preparation
US4489092A (en) * 1976-08-06 1984-12-18 Schering Aktiengesellschaft Prostanoic acid derivatives and their preparation
US4123441A (en) * 1976-09-22 1978-10-31 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
US4499293A (en) * 1976-09-22 1985-02-12 The Upjohn Company PGI2 Salts
US4089885A (en) * 1976-11-05 1978-05-16 American Home Products Corporation Prostaglandin derivatives
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4225508A (en) * 1979-07-05 1980-09-30 The Upjohn Company 19-Hydroxy-PGI2 compounds
US4225507A (en) * 1979-07-05 1980-09-30 The Upjohn Company 19-Hydroxy-19-methyl-PGI2 compounds
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4704386A (en) * 1985-08-29 1987-11-03 G. D. Searle & Co. 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides
US5280018A (en) * 1986-06-09 1994-01-18 American Cyanamid Company Vehicle for optical application of pharmaceuticals
US4889845A (en) * 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
US5663203A (en) * 1986-09-11 1997-09-02 Schering Aktiengesellschaft Agents containing prostacyclin derivatives for topical application
US5500230A (en) * 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5973002A (en) * 1987-02-16 1999-10-26 Froelich; Juergen C. Prostaglandin E1 derivatives as pharmacologically active agents, especially for transcutaneous administration
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US5464868A (en) * 1987-02-16 1995-11-07 Froelich; Juergen C. Prostaglandin E1 derivatives for transdermal administration and methods of treatment therewith
US5681850A (en) * 1987-02-16 1997-10-28 Froelich; Juergen C. Method of treatment of impotence with prostaglandin E1 derivatives
US5770759A (en) * 1987-04-30 1998-06-23 R-Tech Ueno, Ltd. Prostaglandins of the F series
US6030999A (en) * 1988-09-06 2000-02-29 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5063057A (en) * 1990-09-26 1991-11-05 Elizabeth Arden Co., Division Of Conopco, Inc. Cosmetic capsules
US5576315A (en) * 1991-05-03 1996-11-19 G.D. Searle & Co. Substituted dibenzoxazepine compounds and methods for treating osteoporosis and ischemia
US5641494A (en) * 1992-03-20 1997-06-24 Janssen Pharmaceutica N.V. Agent for regulating the greasiness of the skin
US5578640A (en) * 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5605931A (en) * 1992-05-20 1997-02-25 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5578643A (en) * 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5422371A (en) * 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
US5508303A (en) * 1992-05-29 1996-04-16 Toray Industries, Inc. Hair-growing composition
US6013823A (en) * 1992-06-08 2000-01-11 New Pharma International Corp. Trans-pentavalent 2-15-deoxy-16-hydroxy-16-methyl-PGE1 methyl ester (B-407)
US6037364A (en) * 1992-09-21 2000-03-14 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5340813A (en) * 1992-11-09 1994-08-23 Cell Therapeutics, Inc. Substituted aminoalkyl xanthine compounds
US5567079A (en) * 1992-11-17 1996-10-22 Felder; Anton Method for the hydraulic branching of an open stream and hydraulically working channel branch
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US5719140A (en) * 1993-04-30 1998-02-17 G.D. Searle & Co. 2, 3-, 4-, 5-, 6-, 7-, 8-, 9- and /or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5985597A (en) * 1993-05-26 1999-11-16 Merck Frosst Canada, Inc. DNA encoding prostaglandin receptor EP1
US6031079A (en) * 1993-05-26 2000-02-29 Merck Frosst Canada, Inc. Purified prostaglandin receptor EP1
US5869281A (en) * 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
US5840847A (en) * 1993-06-25 1998-11-24 Merck Frosst Canada, Inc. Purified prostaglandin receptor FP
US5889052A (en) * 1993-08-03 1999-03-30 Alcon Laboraties, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US5759789A (en) * 1993-08-31 1998-06-02 Merck Frosst Canada, Inc. Prostaglandin receptor EP2
US5516652A (en) * 1993-10-06 1996-05-14 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor IP
US6025375A (en) * 1993-12-20 2000-02-15 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole derivatives
US5587391A (en) * 1993-12-28 1996-12-24 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6031001A (en) * 1994-09-21 2000-02-29 Synphra Ab Use of prostaglandins
US5885974A (en) * 1994-12-06 1999-03-23 Michael M. Danielov Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
US6043264A (en) * 1995-01-06 2000-03-28 Toray Industries, Inc. Benzene-condensed heterocyclic derivatives and their uses
US5958723A (en) * 1995-01-26 1999-09-28 Merck Frosst Canada & Co. DNA encoding prostaglandin receptor DP
US5885766A (en) * 1995-02-17 1999-03-23 Societe L'oreal S.A. Method of screening of substances for their effect on the expression of mediators of inflammation in a hair follicle
US5990346A (en) * 1995-06-26 1999-11-23 Teijin Limited Prostaglandins and processes for production thereof
US5972965A (en) * 1995-07-21 1999-10-26 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryl oxazole derivatives
US5716609A (en) * 1995-07-25 1998-02-10 Panacea Biotec Limited Therapeutic anti-inflammatory and analgesic composition containing nimesulide for use transdermally and a process for the manufacture thereof
US5994397A (en) * 1995-12-22 1999-11-30 Alcon Laboratories, Inc. Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US6025392A (en) * 1995-12-22 2000-02-15 Alcon Laboratories, Inc. substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
US5658897A (en) * 1996-04-08 1997-08-19 Allergan Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents
US5792851A (en) * 1996-09-03 1998-08-11 Albert Einstin College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Human prostaglandin transporter
US5892099A (en) * 1997-01-27 1999-04-06 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
US6262105B1 (en) * 1997-02-04 2001-07-17 Murray A. Johnstone Method of enhancing hair growth
US6110969A (en) * 1997-02-04 2000-08-29 Ono Pharmaceutical Co. Ltd. Cycloalkyl-prostaglandin E2 derivatives
US6030959A (en) * 1997-04-04 2000-02-29 Monsanto Company Gastro-specific prodrugs
US6037368A (en) * 1997-05-09 2000-03-14 Mount Sinai School Of Medicine 8-iso- prostaglandins for glaucoma therapy
US5977173A (en) * 1997-09-09 1999-11-02 Wos; John August Aromatic C16 -C20 -substituted tetrahydro prostaglandins useful as FP agonists
US6048895A (en) * 1997-09-09 2000-04-11 The Procter & Gamble Company Aromatic C16-C20 substituted tetrahydro prostaglandins useful as FP agonists
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43372E1 (en) 1999-03-05 2012-05-08 Duke University C16 unsaturated FP-selective prostaglandins analogs
US20060121069A1 (en) * 2000-03-31 2006-06-08 Duke University Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US9579270B2 (en) 2000-03-31 2017-02-28 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9346837B2 (en) 2000-03-31 2016-05-24 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20060247214A1 (en) * 2000-03-31 2006-11-02 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US8906962B2 (en) 2000-03-31 2014-12-09 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US8618086B2 (en) 2000-03-31 2013-12-31 Duke University Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20090286769A1 (en) * 2000-03-31 2009-11-19 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US8541466B2 (en) 2000-03-31 2013-09-24 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9675539B2 (en) 2000-03-31 2017-06-13 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US7795302B2 (en) 2001-05-09 2010-09-14 The Regents Of The University Of Michigan Use of compositions for treating rosacea
US7078048B2 (en) * 2001-05-09 2006-07-18 The Regents Of The University Of Michigan Method and compositions for treating rosacea
US20020183399A1 (en) * 2001-05-09 2002-12-05 Sewon Kang Method and compositions for treating rosacea
US20080033036A1 (en) * 2003-08-12 2008-02-07 Ryuji Ueno Composition and Method for Promoting Hair Growth
US8686035B2 (en) 2003-08-12 2014-04-01 R-Tech Ueno, Ltd. Composition and method for promoting hair growth
US8642644B2 (en) 2004-10-21 2014-02-04 Duke University Ophthamological drugs
US20090318542A1 (en) * 2004-10-21 2009-12-24 Toone Eric J Ophthamological drugs
US20060135609A1 (en) * 2004-10-21 2006-06-22 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US20100221197A1 (en) * 2007-11-27 2010-09-02 Taiyo Corporation Antimicrobial agent and external preparation for skin containing the same
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100105775A1 (en) * 2008-10-29 2010-04-29 Delong Mitchell A Amino acid salts of prostaglandins
US9006291B2 (en) 2009-02-03 2015-04-14 Pharma Patent Holding Inc. Composition, method and kit for enhancing hair

Also Published As

Publication number Publication date Type
JP2003528897A (en) 2003-09-30 application
CA2401718A1 (en) 2001-10-11 application
DE60115869T2 (en) 2006-07-06 grant
EP1267803B1 (en) 2005-12-14 grant
JP5579158B2 (en) 2014-08-27 grant
DE60115869D1 (en) 2006-01-19 grant
US7407987B2 (en) 2008-08-05 grant
CN1206976C (en) 2005-06-22 grant
US20070092466A1 (en) 2007-04-26 application
US8618086B2 (en) 2013-12-31 grant
CN1419437A (en) 2003-05-21 application
ES2254395T3 (en) 2006-06-16 grant
EP1267803A2 (en) 2003-01-02 application
WO2001074313A2 (en) 2001-10-11 application
CA2401718C (en) 2007-05-29 grant
US20080241078A1 (en) 2008-10-02 application
JP2012046545A (en) 2012-03-08 application
WO2001074313A3 (en) 2002-02-21 application

Similar Documents

Publication Publication Date Title
US4490353A (en) Antiplaque dentifrice with improved fluoride stability
US6124362A (en) Method for regulating hair growth
US4522806A (en) Oral compositions for hexetidine and zinc salts for the synergistic inhibition of dental plaque
US5833958A (en) Dentifrice compositions
US4137306A (en) Anhydrous antiperspirant stick compositions
US4289754A (en) Zinc derivatives and their use in mouthwash compositions
US20080070988A1 (en) Method of Enhancing Hair Growth
US20020044953A1 (en) Use of non-prostanoic agonists of prostaglandin EP-2 and/or EP-4 receptors as cosmetic agents for attenuating, reducing or stopping the loss of head hair and other hairs
US20050058614A1 (en) Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
US4146607A (en) Synergistic anti-plaque mixture with tetradecylamine plus aluminum and/or zinc
US6344461B1 (en) Treating skin wrinkles/fine lines with calcium channel inhibitors
US5300289A (en) Phytate antimicrobial compositions in oral care products
US4661342A (en) Oral compositions comprising hydroxamic acids and salts thereof
Hellberg et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist
US20040115234A1 (en) Cosmetic composition
US6482857B1 (en) Compositions which contain triterpenes for regulating hair growth
WO2002007685A2 (en) Method of regulating hair growth using metal complexes of oxidized carbohydrates
US5962508A (en) Retinoid receptor agonists for promoting hair growth and/or retarding hair loss
US5279616A (en) Hair dye compositions and process comprising and utilizing a combination of isatin and aminopyridine derivatives
EP0508524A1 (en) Use of zinc ions for the treatment of periodontitis
US6488922B1 (en) Hair growth promoter
WO2000018733A1 (en) Heterocyclic 2-substituted ketoamides useful for treating hair loss in mammals
WO2000018725A1 (en) 2-substituted ketoamides
WO2004010968A1 (en) Non-amphoteric glutathione derivative compositions for topical application
US6525094B1 (en) Method of treating hair loss using diphenylether derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: PROCTER & GAMBLE COMPANY, THE, OHIO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DELONG, MITCHELL ANTHONY;MOLVER, JOHN MCMILLAN;YOUNGQUIST, ROBERT SCOTT;REEL/FRAME:012943/0837

Effective date: 20010126

AS Assignment

Owner name: DUKE UNIVERSITY, NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROCTER & GAMBLE COMPANY, THE;REEL/FRAME:014462/0584

Effective date: 20040323